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Upon antigen receptor stimulation in both B and T lymphocytes, the signaling 
adapter CARD11 transforms from a closed inactive state to an open active scaffold 
that assembles into a multiprotein complex, leading to the activation of NF-κB, a 
critical pleiotropic transcription factor of the immune system.  This scaffold 
transition is dysregulated by diffuse large B cell lymphoma (DLBCL)-associated 
oncogenic CARD11 mutations in humans that induce constitutive NF-κB activation 
and allow for the uncontrolled proliferation of cancer cells.  Since these mutations 
had only been discovered within the Coiled-coil domain of CARD11, according to the 
existing signaling model, we speculate that similar oncogenic mutations also exist 
within the CARD domain.  Using PCR-based domain random mutagenesis and a 
high-throughput quantitative signaling screen, we indeed identify 24 novel gain-of-
function CARD11 missense mutations in the CARD domain and define a 19-residue 
mutational hotspot between the CARD and the Coiled-coil domain as the LATCH 
domain.  Further mechanistic studies reveal that these hyperactive CARD11 mutants 
disrupt inhibitory domain binding, enhance Bcl10 association and its K63-linked 
ubiquitination, and promote human lymphoma cell survival.  We also identify 
TRAF2 and TAK1 as required cofactors during the induction of K63-linked 
ubiquitination of Bcl10.  When combining the most active CARD11 missense 
mutations in both the CARD and the Coiled-coil domain, we identify a super mutant 
that synergizes the signaling activities of two oncogenic CARD11 missense 
mutations – C49Y and L251P.  Protein complex purification of this super mutant 
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along with mass spectrometry analysis identifies several CARD11 signaling 
cofactors including Bcl10, Malt1, IKKγ, CK1α and STUB1, in addition to a list of 
putative cofactors such as USP7, UBE3C, CKIIα, IGBP1, 14-3-3ε and EFHD2.  
Altogether, our study develops a highly efficient method for the discovery of 
mutational variants that promote tumorigenesis of NF-κB-dependent lymphomas, 
establishes a library of hyperactive CARD11 mutations with oncogenic potential, 
and provides a mechanistic understanding of how these mutants dysregulate the 
NF-κB signaling pathway.  In addition, our data uncover critical components during 
the assembly of Bcl10 ubiquitination, a novel super-hyperactive CARD11 mutant, 
and several putative protein regulators of the CARD11 scaffold complex that are 









Ph.D. DISSERTATION REFEREES 
Joel L. Pomerantz, Ph.D., Associate Professor of Biological Chemistry (advisor) 





 I am extremely grateful to my advisor, Joel Pomerantz, for all of his support 
and guidance throughout my entire graduate career.  As a considerate mentor, Joel 
has been dedicated to offer his graduate students with an excellent nurturing 
environment.  As a patient teacher, Joel has taught me very useful lessons about how 
to design my experiments with appropriate controls and troubleshooting strategies.  
As a skillful public speaker, Joel has shown me how to craft a fascinating oral 
presentation, an ingenious research proposal, and a concise publication manuscript.  
As a responsible scientist, Joel has always been encouraging about our scientific 
career, even amid the worst funding environment in decades.  I am truly fortunate 
to be exposed to this remarkable quality of research training from Joel, without 
whom none of this dissertation work would have been possible. 
 The Pomerantz lab has been a very comfortable workplace for my studies 
throughout all these years, thanks to both the former and current lab members.  I 
am particularly grateful to our former lab technician, Thomas Schaffer, for his 
fantastic pioneering work on the initial screening of novel CARD11 mutations; three 
former graduate students, Ryan McCully, Rebecca Lamason, and Stefanie Lew, for 
laying a solid foundation of biochemical assays for me to build upon.  I have been 
especially impressed and inspired by the professional and respectful spirit of 
Rebecca, with whom I had countless troubleshooting conversations and insightful 
discussions.  I would also like to thank our current lab technicians, Zhaoquan Wang 
and Julia Tritapoe, for their endless dedication to our routine lab maintenance. 
v 
 
 Regarding research tools and reagents, I would like to thank the Synthesis & 
Sequencing Facility at Hopkins, for over hundreds of plasmid sequencing requests; 
Rakhi Jattani, for her assistance in generating the KD-CARD11 Jurkat T cell line; 
Corinne Hamblet, for introducing the Serial Cloner software to our lab; Richard 
Davis, for providing us the OCI-Ly3 ABC-DLBCL cell line; Hongxia Hu and Gregg 
Semenza, for sharing the pSUPER.retro.neo+GFP plasmid with us; Shinya Yamanaka, 
for sharing the pLenti6-Ubc-Slc7a1 ecotropic receptor plasmid via Addgene; Chao 
Lu, for sharing the Amicon filters and his technical experience in protein complex 
purification; Yongkang Yang, for his assistance during the final scale-up purification 
of mutant CARD11 (C49Y+L251P) protein complexes; Ross Tomaino, for the mass 
spectrometry identification services provided through the Taplin Facility at Harvard. 
 Having the great fortune to attend Hopkins for graduate studies is a critical 
step in my research career.  This medical campus is always surrounded by various 
kinds of intellectual-stimulating seminars and discussions, where novel ideas are 
constantly being generated among physicians and scientists.  Therefore, I am very 
grateful to the Immunology graduate program for recruiting me into this wonderful 
research environment and providing stipend support for my initial years of studies.  
Here I would also like to thank my thesis committee members: Ranjan Sen, Stephen 
Desiderio, Jonathan Powell, and Peter Espenshade, for their critical suggestions and 
helpful discussions during our meetings. 
 Finally, I have to thank my parents back in Macau, for sending me to the 
United States for college education and always being so supportive of my research 
career.  I would also like to thank my wife, Iris, for her love and support. 
vi 
 
Table of Contents 
Abstract                                                                                                                                               ii 
Acknowledgements                                                                                                                         iv 
Table of Contents                                                                                                                             vi 
List of Tables                                                                                                                                   viii 
List of Figures                                                                                                                                    ix 
Chapter I:  Overview                                                                                                                         1 
      Antigen Receptor Signaling to NF-κB                                                                                    2 
      Dysregulation of NF-κB Signaling in Lymphoma                                                               4 
Chapter II:  A Quantitative Signaling Screen Identifies CARD11 Mutations in the   
CARD and LATCH Domains That Induce Bcl10 Ubiquitination and Human 
Lymphoma Cell Survival                                                                                                                 7 
      Abstract                                                                                                                                          8 
      Introduction                                                                                                                                  8 
      Experimental Procedures                                                                                                       12 
      Results                                                                                                                                          21 
      Discussion                                                                                                                                   31 
Chapter III:  Identification of Putative Protein Regulators of the CARD11 Signaling  
Complex and K63-linked Ubiquitination of Bcl10                                                                60 
      Abstract                                                                                                                                        61 
      Introduction                                                                                                                               62 
      Experimental Procedures                                                                                                       64 
vii 
 
      Results                                                                                                                                          68 
      Discussion                                                                                                                                   75 
Chapter IV:  Discussion                                                                                                                 90 
      Hyperactive CARD11 Mutations in the CARD and LATCH Domains                         91 
      Super-hyperactive Mutant and Putative Regulators of the CBM Complex              95 




















List of Tables 























List of Figures 
Figure 2.1:  A quantitative signaling screen identifies gain-of-function mutations  
                       in the CARD and LATCH domains of CARD11.                                                38 
Figure 2.2:  Relative Specific Activity of CARD11 variants in HEK293T and Jurkat  
                       T cells.                                                                                                                          40 
Figure 2.3:  Mutations in the CARD and LATCH domains enhance the ability of  
                       CARD11 to associate with Bcl10.                                                                        42 
Figure 2.4:  Gain-of-function mutations enhance Bcl10-mediated association of  
                       MALT1 with CARD11.                                                                                             44 
Figure 2.5:  Mutations in the CARD and LATCH domains disrupt ID binding  
                       in trans.                                                                                                                       46 
Figure 2.6:  Hyperactive CARD11 variants require Bcl10 for NF-κB activation.         49 
Figure 2.7:  Hyperactive variants require MALT1, TRAF6, and TAK1 for NF-κB  
                       activation.                                                                                                                   51 
Figure 2.8:  Hyperactive CARD11 variants induce K63-linked Ubiquitination of 
                       Bcl10 and the association of Ubn(K63)-Bcl10 with IKKγ.                            53 
Figure 2.9:  CARD11 variants containing gain-of-function mutations in the CARD  
  and LATCH domains can promote the survival of OCI-Ly3 human  
                       DLBCL-derived cells.                                                                                               56 
Figure 2.10:  Model depicting how gain-of-function mutations in the CARD,  
    LATCH, and Coiled-coil domains spontaneously induce NF-κB  
                         activation.                                                                                                                 58 
x 
 
Figure 3.1:  An E3 ubiquitin ligase TRAF2 and TAK1 kinase are required for  
                       PMA/ionomycin-induced K63-linked ubiquitination of Bcl10.                 79 
Figure 3.2:  Oncogenic CARD11 mutations C49Y (CARD) and L251P (Coiled-coil)    
  synergize their respective signaling capacity to generate a super- 
  hyperactive mutant that no longer requires PDZ, L3, SH3, L4 or GUK  
                       for signaling to NF-κB.                                                                                            81 
Figure 3.3:  Super-hyperactive mutant C49Y+L251P enhances the ability of  
  CARD11 to associate with Bcl10 and MALT1, but not other signaling  
                        cofactors.                                                                                                                   84 
Figure 3.4:  Several putative CARD11 signaling cofactors were identified through  
  protein complex purification of the super-hyperactive CARD11  
































Antigen Receptor Signaling to NF-κB 
The pleiotropic transcription factor NF-κB is an important master regulator 
of cellular responses to various kinds of intracellular and extracellular stimulations 
including pro-inflammatory cytokines (such as TNF, IL-1 and IL-17), cellular 
stresses (such as ROS, UV and DSB), pathogen-associated molecular patterns 
(PAMPS), and the engagement of immunoreceptors (such as TCR and BCR) (1).  In 
mammalian cells, the NF-κB proteins exist as homodimers or heterodimers 
consisting of p50/p105 (NF-κB1), p52/p100 (NF-κB2), p65 (RelA), RelB, and c-Rel, 
all of which contain a conserved N-terminal Rel homology domain (RHD) that 
mediates dimerization, IκB (inhibitor of NF-κB) and DNA binding (2).  In the resting 
state, NF-κB remains in the cytoplasm due to its binding to IκB; upon cellular 
stimulation, activated IκB kinase (IKK) complex phosphorylates IκB, leading to its 
polyubiquitination and subsequent degradation by the 26S proteasome, thereby 
unmasking the nuclear localization signal (NLS) of NF-κB and allowing for its 
nuclear translocation (3).  Target genes that are exposed to transcriptional 
regulation by NF-κB include cytokines (such as TNF, IL-1, IL-6 and IL-12), pro-
survival and pro-proliferative molecules (such as Cyclin-D1, Bcl-xL, cFLIP and IAPs), 
antimicrobial products, non-coding micro-RNAs, adhesion and matrix-remodeling 
molecules (such as VCAM, ICAM and E-selectin), and lymphocyte activation and 
differentiation markers (such as IL-2, B7, MHC, Foxp3 and ROR) (1).  As these 
transcriptional programs represent important biological functions in both innate 
3 
 
and adaptive immune systems, the molecular details of signaling pathways that lead 
to IKK and NF-κB activation have been topics of intense investigation. 
The adaptive wing of immunity relies on the proper functions of both B and T 
lymphocytes, which recognize surrounding antigens by their surface expression of B 
cell receptor (BCR) and T cell receptor (TCR) respectively.  Antigen receptor 
engagement triggers a complex and highly-regulated network of signaling cascades 
that ultimately lead to the activation of several transcription factors including NF-κB, 
NFAT and AP-1.  Among these, the activation of NF-κB is particularly critical for 
lymphocytes and a sustained adaptive immune response as this master regulator 
allows for the survival, activation, growth and proliferation of both B and T 
lymphocytes.  The extent and duration of BCR- and TCR-induced NF-κB activation 
are controlled by a number of mechanisms including the strength of antigen-
receptor interaction with its ligand (antigen or peptide-MHC), the presence or 
absence of co-stimulatory signals (such as CD28, OX40, PD1 and CTLA4), and the 
signaling cascade components that are regulated based on cellular states (4, 5). 
CARD11 (also known as CARMA1 or BIMP3) is a multidomain scaffold 
protein that is indispensable in both BCR- and TCR-induced activation of the IKK 
complex and the canonical NF-κB (p50/p65) (6–12).  Conserved protein domains in 
CARD11 include CARD, Coiled-coil, PDZ, SH3 and GUK, which are separated by four 
intervening linker regions known as L1, Inhibitory Domain (ID) (13), L3 and L4.  
During the latent state, CARD11 is held in a closed inactive conformation by 
intramolecular interactions among the CARD, Coiled-coil and ID domains.  Upon 
antigen receptor signaling, specific serine residues located within the ID are 
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phosphorylated by Protein Kinase C (PKCβ in B cells vs. PKCθ in T cells) and some 
other unidentified kinases (14–17).  This series of posttranslational modifications 
transforms CARD11 into an open active conformation and allows CARD11 to recruit 
multiple positive signaling cofactors including the adapter Bcl10, the paracaspase 
MALT1, the TRAF6 E3 Ligase, the TAK1 kinase, Caspase-8 and IKKγ (13).  Through 
some unclear mechanism, this complex of signaling molecules together activates the 
IKK complex, thereby allowing NF-κB to accumulate in the nucleus to regulate target 
genes.  The CARD11-nucleated signaling complex is transient and disassembles 
following IKK complex activation, presumably returning CARD11 to an inactive state. 
 
Dysregulation of NF-κB Signaling in Lymphoma 
 While the proper spatiotemporal onset of NF-κB activation can serve as a 
powerful master regulator to program B and T lymphocytes for mounting a host-
protective immune response, it could become detrimental to the host when NF-κB 
activation is dysregulated and leads to diseases such as immunodeficiency, 
autoimmunity and various types of cancer (18).  Therefore, the activation level of 
NF-κB must be exquisitely tuned by the immune system in order to prevent chaotic 
malfunction in either direction.  Aberrant NF-κB activity likely contributes to 
oncogenesis through the unregulated transcriptional induction of pro-proliferative 
and anti-apoptotic genes that confer a survival advantage to transformed cells.  In 
human lymphomas, somatic mutations often emerge to target signaling pathway 
components that are normally regulated by antigen receptor signaling. 
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 Diffuse Large B Cell Lymphoma (DLBCL), the most common type of non-
Hodgkin’s lymphoma, is classified into three subtypes based on gene expression 
profiles: 1) activated B-cell-like (ABC) subtype; 2) germinal center B-cell-like (GCB) 
subtype; 3) primary mediastinal B-cell lymphoma (PMBL) (19).  Characterized by 
constitutive activation of NF-κB, ABC-DLBCL is the least curable subtype with a 5-
year survival rate of only 30% and poor prognosis.  Interestingly, several oncogenic 
CARD11 mutations, almost exclusively located within the Coiled-coil domain, have 
been identified in patient-derived cell lines and biopsies from both ABC- and GCB-
DLBCL (20).  These Coiled-coil domain mutations were thought to dysregulate 
CARD11 signaling to NF-κB by enhancing the oligomerization state of CARD11, 
although this mechanism remains controversial and lacks biochemical evidence. 
 Recently, a more detailed molecular mechanism was elucidated (21) for two 
oncogenic CARD11 mutations that were identified in human DLBCL: F123I and 
L225LI (both located within the Coiled-coil domain).  Without significant alteration 
of CARD11 oligomerization state, these two mutations were found to cause 
hyperactivity by disrupting the autoinhibitory CARD-Coiled-coil-ID binding that 
normally keeps CARD11 in a closed, inactive conformation in the absence of antigen 
receptor signaling.  In addition, the F123I and L225LI mutations specifically 
enhance Bcl10 and (Bcl10-mediated) MALT1 recruitment to CARD11, suggesting the 
spontaneous formation of the CARD11-nucleated signaling complex.  Upon TCR 
stimulation, K63-linked polyubiquitin chains are conjugated to Bcl10 on its K31 and 
K63 residues, in a process that requires both CARD11 and MALT1 (22).  This 
modified form of Bcl10 occurs transiently and associates with IKKγ, presumably to 
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relay upstream activation signals to the IKK complex.  The F123I and L225LI 
oncogenic mutations require Bcl10 residues K31 and K63 for hyperactive NF-κB 
signaling, indicating that Bcl10 ubiquitination is a target of dysregulation in DLBCL. 
 A critical question that emerged from the above study is whether oncogenic 
mutations utilizing similar molecular mechanisms could be identified from the 
CARD or the ID domain, assuming that mutations in these two domains are also 
sufficient to disrupt the CARD-Coiled-coil-ID autoinhibitory binding.  We will 
address this issue in the next Chapter.  Another critical question that remained 
unclear is whether there are other unidentified protein cofactors that get recruited 
to these hyperactive CARD11 signaling complexes.  This issue will be discussed in 
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Antigen receptor signaling to NF-κB, essential for normal lymphocyte activation, is 
dysregulated in several types of lymphoma.  During normal signaling, the 
multidomain adapter CARD11 transitions from a closed, inactive state to an open, 
active scaffold that assembles a multiprotein complex, leading to NF-κB activation.  
The regulation of CARD11 scaffold function is bypassed by lymphoma-associated 
oncogenic CARD11 mutations that induce spontaneous signaling.  We report an 
unbiased high-throughput quantitative signaling screen that identifies new CARD11 
hyperactive variants and defines a LATCH domain that functions with the CARD to 
promote CARD11 autoinhibition.  Gain-of-function mutations in the LATCH or CARD 
disrupt Inhibitory Domain binding, promote Bcl10 association, and induce Bcl10 
ubiquitination, NF-κB activation, and human lymphoma cell survival.  Our results 
identify CARD11 mutations with oncogenic potential, provide a mechanistic 
explanation for their signaling potency, and offer a straightforward method for the 




 The activation of the NF-κB transcription factor by antigen receptor signaling 
is critical for lymphocyte activation during the adaptive immune response (23).  NF-
κB controls a variety of genes that participate in lymphocyte proliferation, survival, 
and differentiation, and the induction of NF-κB activity by antigen is tightly 
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regulated.  Prior to antigen receptor engagement, NF-κB is held inactive in the 
cytoplasm of cells by the IκB family of inhibitory proteins. Antigen receptor 
signaling results in the activation of the IKK kinase complex, which phosphorylates 
IκBs, targeting them for ubiquitination and degradation, and allowing NF-κB to 
accumulate in the nucleus to regulate target genes.  The extent and duration of NF-
κB activation downstream of antigen recognition at the surface of B and T 
lymphocytes is controlled by a variety of mechanisms. These include the strength of 
antigen:receptor interaction, the presence or absence of concomitant costimulatory 
signaling, and the action of signaling cascade components that control the 
magnitude of signaling output as it is being induced or that provide negative 
feedback to terminate signaling (4, 5).   
 The exquisite regulation of NF-κB activity by the antigen receptor signaling 
pathway is disrupted in a variety of cancers of the immune system (18). Aberrant 
NF-κB activity likely contributes to oncogenesis through the unregulated 
transcriptional induction of pro-proliferative and anti-apoptotic genes that confer a 
survival advantage to transformed cells.  Multiple mechanisms have been described 
by which lymphoid cancers achieve dysregulated NF-κB activation, including, for 
example, the overexpression or gain-of-function mutation of proteins that signal 
upstream of the IKK complex, the deletion or loss-of-function of inhibitory proteins 
that downmodulate or terminate signaling, and the overexpression of subunits of 
NF-κB itself (24). 
 CARD11 (CARMA1, BIMP3) is a multidomain scaffold protein that is required 
for B cell receptor (BCR) and T cell receptor (TCR)-mediated activation of the IKK 
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complex (6–12).  CARD11 contains CARD, Coiled-coil, PDZ, SH3, and GUK domains, 
separated by four intervening regions.  As a consequence of BCR or TCR engagement, 
CARD11 undergoes a conformational transition from a closed, inactive state to an 
open, active scaffold. This transition is controlled by an Inhibitory Domain (ID), 
located between the Coiled-coil and PDZ domains, that keeps CARD11 in the closed, 
latent state through interactions that require the CARD and Coiled-coil domains 
(13–15).  Antigen receptor signaling leads to the neutralization of the ID through its 
phosphorylation at specific serine residues by PKCθ in T cells, PKCβ in B cells, IKΚβ, 
and at least one additional unidentified kinase (14–17, 25). Subsequent to ID 
neutralization, CARD11 recruits several positive signaling cofactors into a complex, 
including the adapter Bcl10, the paracaspase MALT1, the TRAF6 E3 ligase, the TAK1 
kinase, Caspase-8, and IKKγ (13).  The formation of this complex is thought to elicit 
the activation of IKK kinase activity through the scaffolding and catalytic activities of 
each complex component, although the exact mechanistic details of how IKK kinase 
activity is engaged remain poorly defined.  The CARD11-nucleated signaling 
complex is transient; following IKK activation, the complex disassembles, 
presumably returning CARD11 to the inactive state. 
 CARD11-dependent signaling is dysregulated in Diffuse Large B Cell 
Lymphoma (DLBCL), which has been divided into several subtypes based upon gene 
expression signatures (19).  The Activated B Cell-like (ABC) subtype is characterized 
by constitutive activation of NF-κB, which is required for the proliferation and 
survival of ABC-derived cell lines in culture (26).  An RNAi screen for genes required 
for this aberrant signaling to NF-κB revealed obligate roles for CARD11, Bcl10 and 
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MALT1 (27).  In addition, approximately 10% of human ABC DLBCL samples 
examined by Lenz et al. exhibited gain-of-function mutations in CARD11 that 
conferred the protein with hyperactive signaling ability, thereby explaining in those 
cases the origin of the unregulated induction of NF-κB activity (28).  Interestingly, 
most of the hyperactive mutations reported in DLBCL occurred in the Coiled-coil 
domain. 
 Recently, we characterized two oncogenic CARD11 mutations, F123I and 
L225LI, found in human DLBCL, and provided evidence that these mutations cause 
hyperactivity by disrupting the normal autoinhibition by the ID that keeps CARD11 
inactive prior to receptor engagement, resulting in the spontaneous conversion of 
CARD11 from the closed, inactive state, to the open, active state in the absence of 
receptor triggering or ID phosphorylation (21). The F123I and L225LI mutations 
partially disrupted intramolecular binding of the ID and specifically enhanced the 
ability of CARD11 to associate with Bcl10, but not with several other cofactors 
examined. Signaling downstream of F123I and L225LI required Bcl10, and the 
ubiquitination of Bcl10 on K31 and K63 (21), a signaling step required for normal 
TCR signaling (22). 
 These findings provided a satisfying explanation for how mutations in the 
Coiled-coil could cause hyperactivity, since the Coiled-coil domain is one of the 
regions targeted by the ID in the inactive state.  The results also predicted that any 
mutation that disrupts the ability of the ID to auto-inhibit CARD11 signaling should 
result in gain-of-function hyperactivity.  However, most of the described human 
DLBCL mutations were found in the Coiled-coil domain and not, for example, in the 
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CARD domain, which has also been shown to be required for the intramolecular ID 
association that keeps CARD11 in the closed inactive state. The apparent 
concentration of oncogenic mutations in the Coiled-coil domain raised the question 
as to how frequently gain-of-function mutations occur outside the Coiled-coil 
domain, and if so, whether such mutations might confer a signaling potency 
comparable to those found in human DLBCL and achieve hyperactivity by the same 
mechanisms. In this report we address these questions by characterizing novel gain-
of-function CARD11 mutants that we identified in a quantitative high-throughput 




Primary and secondary screens for CARD11 gain-of-function mutations 
A library of murine CARD11 variants containing random mutations between 
amino acid residues 1 and 138 was generated in the context of pc-CARD11 (13) by 
error-prone PCR under conditions that favored one mutation per clone using the 
GeneMorph II EZClone Domain Mutagenesis Kit (Stratagene) and primers 5’-
GGATCCACTAGTAACGGCCGCC-3’ and 5’-GCAGTTTGATGACCTCGTTCATCAG-3’ 
according to the manufacturer's protocol. A total of 2220 individual clones were 
screened by transiently transfecting 50 ng of each clone, 20 ng of Igκ2-IFN-LUC and 
6 ng of CSK-LacZ into HEK293T cells in 24-well plates by the calcium phosphate 
method and assaying reporter activities as previously described (13).  Each clone 
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that activated the Igκ2-IFN-LUC reporter at least 3-fold more than wild-type 
CARD11 was considered positive and sequenced to identify its mutation.  The region 
containing the identified mutation was recloned into the parental pc-CARD11 
backbone and re-assayed to confirm hyperactivity. 
 
Determination of specific activities in HEK293T and Jurkat T cells 
Each verified mutant was titrated at subsaturating levels, between 1.5 and 27 
ng, into the Igκ2-IFN-LUC reporter assay in HEK293T cells, and protein 
concentration was determined by densitometric analysis of western blots as 
described previously (21).  Relative specific activity was determined by taking the 
fold Igκ2-IFN-LUC reporter activation elicited by a mutant at the same protein 
expression at which wild-type CARD11 elicited 3-fold activation and dividing by 3.  
CARD11-KD Jurkat T cells were transfected with Igκ2-IFN-LUC and CSK-LacZ as 
previously described (13) using 50-90 ng of expression construct for each CARD11 
variant to achieve equivalent protein expression level.  The relative activity in T cells 
was determined by taking the fold Igκ2-IFN-LUC reporter activation elicited by a 
mutant and dividing by the fold achieved by wild-type CARD11 at the comparable 
level of expression. 
 
Immunoprecipitations in HEK293T cells 
One day prior to transfection, 5x105 HEK293T cells were plated in each well 
of a six-well plate.  A total of 2 μg DNA per well was transfected using the calcium 
phosphate method.  The medium was changed 22 to 26 h posttransfection, and the 
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cells were harvested 42 to 46 h posttransfection.  Cells were lysed in 300 or 500 μl 
of immunoprecipitation lysis buffer (IPLB) and debris was removed as described 
previously (13).  6 or 20 μl of cell lysate was saved for western blot analysis and 264 
or 450 μl was incubated with 1 μg of anti-FLAG antibody (Sigma F7425) for 90 to 
120 min at 4°C with rotation.  7 or 10 μl bed volume of protein G-Sepharose 4 Fast 
Flow (GE Healthcare) was added and incubated for 90 to 120 min at 4°C with 
rotation.  The resulting immunocomplex was washed with IPLB four times for 5 min 
at 4°C with rotation, eluted twice, pooled, and resolved for western blot analysis as 
described previously (21) using anti-myc (sc-40; Santa Cruz), anti-FLAG (M2; 
Eastman Kodak IB13026 or Sigma F1804), and anti-Bcl10 (sc-5273; Santa Cruz). 
The levels of each CARD11 variant in the input and the IP were determined by 
densitometric analysis of subsaturating exposures of western blots using ImageJ. To 
quantitate Bcl10 binding for each variant, the ratio of the quantity of the variant in 
the IP divided by that in the input was determined and then normalized to the ratio 
achieved by the ΔID.  
 
Glutathione-Sepharose Pull Downs 
Gain-of-function mutations were introduced into the context of pc-ΔID (13).  
pEBB-HA-ID-GST (13), pEBG (13) and each pc-ΔID variant were transfected 
separately into HEK293T cells and harvested as described above.  Cells from each 
well of a six-well plate were lysed in 500 μl of IPLB and debris was removed as 
described above.  Between 0.2 and 5.4% of lysates was first analyzed by western 
blot to quantify the protein expression of each ΔID variant.  A titration of ΔID 
15 
 
variant-containing extract was mixed with equivalent fractions of extract containing 
either HA-ID-GST or GST, and extract from pcDNA3-transfected cells to make a total 
volume of 500 μl.  Mixed lysates were precleared twice by incubating with 10 μl bed 
volume of Protein G Sepharose for 30 to 50 min at 4°C with rotation.  From the 
precleared mixed lysates, 4.4% was saved as input for western blot analysis and the 
remaining 450 μl was incubated with 10 μl bed volume of Glutathione-Sepharose 
(GE Healthcare) for 15 to 17 h at 4°C with rotation.  Samples were washed and 
analyzed as described previously (13) using anti-myc (sc-40; Santa Cruz) and anti-
GST (sc-459; Santa Cruz).  The levels of each CARD11 variant in the input and the 
pulldown were determined by densitometric analysis of subsaturating exposures of 
western blots using ImageJ.  To quantitate ID binding for each variant, the ratio of 
the quantity of the variant in the pulldown divided by that in the input was 
determined and then normalized to the ratio achieved by the ΔID at a comparable 
level of expression. 
 
Bcl10-deficient HEK293T and CARD11-, MALT1-, and TRAF6-deficient Jurkat T 
cell lines 
The KD-GFP and KD-Bcl10 HEK293T cell lines have been described (13).  
CARD11 variant and Bcl10 expression was assessed in these lines by western blot 
using anti-myc (sc-40; Santa Cruz) and anti-Bcl10 (sc-5273; Santa Cruz).  To 
generate the KD-CARD11 Jurkat T cell line, a self-inactivating lentiviral construct 
based upon the vector pLKO.1 was constructed to express the sihCARD11-2 short 
hairpin RNA (Sense sequence: 5’-TGGTCAAGAAGCTGACGATTC-3’; loop sequence: 
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5’-TTCAAGAGA-3’) downstream of the human U6 RNA promoter.  Lentiviral 
particles were packaged as described previously (29).  After clearing cell debris by 
centrifugation at 2300 x g for 5 min, 100 μl of viral supernatant was added to 1.5 x 
105 Jurkat T cells in a final volume of 300 μl in a 24-well plate.  Approximately 24 h 
post-infection, cells were resuspended in fresh medium containing 0.5 μg/ml 
puromycin and selected for 1 week.  Puromycin-resistant Jurkat T cells were 
maintained in media containing 0.5 μg/ml puromycin. 
 To generate the KD-NT, KD-MALT1, and KD-TRAF6 Jurkat T cell lines, 
pLKO.1-based lentiviruses were constructed to express either shNT (Sigma SHC002; 
Sense sequence: 5’-CAACAAGATGAAGAGCACCAA-3’; loop sequence: 5’-CTCGAG-3’), 
shM1 ((13); Sense sequence: 5’-CCTCACTACCAGTGGTTCAAA-3’; loop sequence: 5’-
CTCGAG-3’), or shT6 ((30); Sense sequence: 5’-CCACGAAGAGATAATGGAT-3’; loop 
sequence: 5’-TTCAAGAGA-3’).  To package these lentiviruses, HEK293T cells were 
plated at 5x105 cells per well in a 6-well plate and transfected 24 h later using 
calcium phosphate with 520 ng pMDL-RRE, 182 ng RSV-Rev, 260 ng pCMV-VSVg, 
and 1040 ng pLKO.1-based vector.  The medium was replaced with 2ml RPMI 22 to 
24 h posttransfection.  Supernatants containing viral particles were harvested 47 to 
48 h posttransfection after clearing cell debris by centrifugation at 18,000 x g for 5 
min.  1 ml of viral supernatant was added to 6x106 Jurkat T cells in a final volume of 
12 ml in a 10-cm plate.  Approximately 24 h post-infection, cells were resuspended 
in fresh RPMI medium containing 0.5 µg/ml puromycin and selected for 10 days. 
Knockdown was assessed by western blot using anti-MALT1 (catalog# 1664-1; 
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Epitomics), anti-TRAF6 (sc-7221; Santa Cruz), and anti-IKKα (sc-7606; Santa Cruz) 
antibodies. 
 
TAK1 inhibition assays 
(5Z)-7-oxozeaenol was obtained from Calbiochem (product code 499610). 
Either DMSO vehicle or 500 nM (5Z)-7-oxozeaenol was added to each sample every 
twelve hours after transfection for a total of three doses and samples were 
harvested 41 hours after transfection. Some samples were stimulated with anti-
CD3/anti-CD28 crosslinking as described (29) for four hours before harvest. 
 
Stable expression of murine CARD11 variants in Jurkat T cells 
Gain-of-function mutations were introduced into the context of pCLIP3A-
myc-CARD11-mCherry (29), a Moloney murine leukemia virus-based vector.  To 
package viruses, HEK293T cells were plated at 5x105 cells per well in a 6-well plate 
and transfected 24 h later using calcium phosphate with 430 ng pCL-SIN-Ampho 
(31), 430 ng pCMV-VSVg (32), and 1140 ng pCLIP3A-myc-CARD11-mCherry-based 
vector.  The medium was replaced with 2 ml RPMI complete medium 22 to 24 h 
posttransfection. Supernatants containing viral particles were harvested 49 to 50 h 
posttransfection after clearing cell debris by centrifugation at 200 x g for 5 min.  For 
each sample, 1.8 ml viral supernatant was added to 5.4 x 106 Jurkat T cells in a final 
volume of 10.8 ml in a 10-cm plate.  Approximately 24 h post-infection, cells were 
resuspended in fresh medium containing 0.5 μg/ml puromycin and selected for 2 
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weeks.  Puromycin-resistant Jurkat T cell lines were maintained in media containing 
0.5 μg/ml puromycin. 
 
NF-κB DNA-binding assays 
Electrophoretic Mobility Shift Assays (EMSA) were done as described (11). 
 
Endogenous Bcl10 and IKKγ immunoprecipitations in Jurkat T cell lines 
The control Jurkat T cell line stably expressing myc-wild-type-CARD11-
mCherry was stimulated with 50 ng/ml PMA (Sigma) and 1 µM ionomycin (Sigma) 
for 20 min at 37°C.  Cells (108 per sample) were then incubated in an ice water bath 
for 5 min, spun at 423 x g for 10 min at 4°C, and lysed in a lysis buffer as described 
previously (33) except that 10% glycerol was added and a different protease 
inhibitor cocktail (Sigma P8340) was used.  Cell lysates were precleared twice with 
20 µl bed volume of Protein A-Sepharose (Sigma P9424) or Protein G-Sepharose for 
1 to 2 h at 4°C with rotation.  To analyze Bcl10 ubiquitination, the precleared lysates 
were denatured and diluted as described previously (22) and then incubated with 4 
μg of anti-Bcl10 (sc-5611; Santa Cruz) antibody for 16 h at 4°C with rotation.  A 20-
μl bed volume of Protein A-Sepharose was added to each sample and incubated for 
20 to 22 h at 4°C with rotation.  To analyze the interaction between IKKγ and 
Ubn(K63)-Bcl10, the precleared lysates were incubated with 3 μg of anti-IKKγ (sc-
8330; Santa Cruz) antibody for 16 h at 4°C with rotation and then incubated with 30 
μl bed volume of Protein G-Sepharose for 4 to 5 h at 4°C with rotation.  Samples 
were washed and analyzed as described previously (13).  Western blots were 
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analyzed using anti-Ub-K63 (14-6077-82; eBioscience), anti-Bcl10 (sc-5273; Santa 
Cruz), anti-myc (sc-40; Santa Cruz), and anti-IKKγ (sc-8032; Santa Cruz). 
 
Stable expression of murine CARD11 variants in OCI-Ly3 cells 
The OCI-Ly3 ABC-DLBCL cell line was a kind gift from Dr. R. Eric Davis (M.D. 
Anderson).  Cells were cultured in OCI medium which contains Iscove’s modified 
Dulbecco medium supplemented with 20% human serum (S40110; Atlanta 
Biologicals), 50 U/ml each of penicillin and streptomycin, and 55 µM of β-
mercaptoethanol in humidified 5% CO2 at 37°C. First, OCI-Ly3 cells stably 
expressing the ecotropic receptor mCAT-1 were generated by infecting cells with 
the lentivirus pLenti6/Ubc/mSlc7a1 (Addgene Plasmid 17224) (34).  To package 
this lentivirus, HEK293T cells were plated at 5x105 cells per well in a 6-well plate 
and transfected 24 h later using calcium phosphate with 1040 ng 
pLenti6/Ubc/mSlc7a1, 520 ng pMDL-RRE (35), 182 ng RSV-Rev (35), and 260 ng 
pCMV-VSVg (32).  The medium was replaced with 2 ml OCI medium 22 to 24 h 
posttransfection.  Supernatants containing viral particles were harvested 47 to 48 h 
posttransfection after clearing cell debris by centrifugation at 423 x g for 5 min.  800 
μl of viral supernatant was added to 1.2 x 106 OCI-Ly3 cells in a final volume of 4.8 
ml in a 6-well plate.  Approximately 48 h post-infection, cells were resuspended in 
fresh OCI medium containing 2 μg/ml blasticidine and selected for 2 weeks.   
 mCAT-1 expressing OCI-Ly3 cells were then infected with the same panel of 
CARD11-mCherry-expressing retroviruses as those used to infect Jurkat T cells. 
pCLIP3A-myc-CARD11-mCherry variants were transfected and packaged as 
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described above.  The medium was replaced with 2 ml OCI medium 22 to 24 h 
posttransfection. Supernatants containing viral particles were harvested 49 h 
posttransfection after clearing cell debris by centrifugation at 18000 x g for 5 min.  
For each sample, 1 ml viral supernatant was added to 1.5 x 106 mCAT-1-expressing 
OCI-Ly3 cells in a final volume of 6 ml in a 10-cm plate.  Approximately 25 h post-
infection, cells were resuspended in fresh OCI medium containing both 0.5 μg/ml 
puromycin and 2 μg/ml blasticidine, and selected for 2 weeks.  Puromycin and 
blasticidine double-resistant OCI-Ly3 cell lines were maintained in OCI medium 
containing both 0.5 μg/ml puromycin and 2 μg/ml blasticidine. Relative levels of 
CARD11 variants were assessed by western blot using anti-myc (sc-40; Santa Cruz), 
anti-CARD11 (cat# 3189; ProSci), and anti-IKKα (sc-7606; Santa Cruz) antibodies. 
 
OCI-Ly3 Proliferation and Survival Assay 
Retroviral constructs based upon the vector pSUPER.retro.neo+GFP (pSRGN, 
Oligoengine) were constructed to express either sihCARD11-2 (Sense sequence: 5’-
TGGTCAAGAAGCTGACGATTC-3’; loop sequence: 5’-TTCAAGAGA-3’) or sihNT 
control (Sense sequence: 5’-TTCTCCGAACGTGTCACGT-3’; loop sequence: 5’-
TTCAAGAGA-3’) (36) short hairpin RNAs (shRNAs) downstream of the H1 RNA 
promoter, and the EGFP gene downstream of the phosphoglycerate kinase promoter.  
To package retroviruses, HEK293T cells were plated at 5x105 cells per well in a 6-
well plate, and transfected 24 h later using Lipofectamine 2000 (Invitrogen) with 
800 ng pCL-Eco (31) and 3200 ng pSRGN-derived construct.  The medium was 
replaced with 1.25 ml OCI medium 25 h posttransfection.  Supernatants containing 
21 
 
viral particles were harvested 55 h posttransfection after clearing cell debris by 
filtration through a 0.45 mm filter.  500 μl of viral supernatant was added to 2 x 105 
OCI-Ly3 cells in a final volume of 1 ml in a 12-well plate, followed by the addition of 
3 μg/ml polybrene.  12 to 18 h post-infection, cells were resuspended in fresh OCI 
medium.  GFP+ percentages measured by FACS 3 days post-infection ranged from 
26.2 to 42.6% as compared to the uninfected OCI-Ly3 control cell line.  Data were 
processed as described previously (27), except that the initial GFP+ data were 
collected 3 days after retroviral transduction. 
 
Results 
Identification of novel gain-of-function mutations in CARD11 in a high-
throughput signaling screen 
Because of the requirement of the CARD domain for intramolecular ID 
association, we hypothesized that some CARD domain residues would mediate 
interactions that maintain CARD11 in the inactive state prior to ID neutralization by 
antigen receptor signaling. To test this hypothesis we adapted screening 
methodology previously used to identify molecules that signal to NF-κB (11) or that 
enhance or suppress the signaling activity of CARD11 (29, 37).   We generated a 
library of CARD11 variants in the context of a mammalian expression vector, in 
which residues between M1 and L138 of murine CARD11 were randomly mutated 
by error-prone PCR. Library clones were screened using a quantitative reporter 
assay in HEK293T cells using the Igκ2-IFN-LUC reporter in a transient transfection 
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to assess NF-κB activation (Figure 2.1A). For normalization of transfection efficiency 
and extract recovery, each transfection also included CSK-LacZ, which constitutively 
expresses β-galactosidase. A clone was considered positive if it activated the 
reporter at least 3-fold more than wild-type CARD11 expressed at a comparable 
level. Positive clones were sequenced to identify mutations, and back-cloned into an 
otherwise wild-type CARD11 expression vector to confirm that the mutation 
identified between residues 1 and 138 was responsible for eliciting the enhanced 
signaling activity.  After screening 2220 clones, we identified 24 gain-of-function 
mutations in this region of CARD11 (Figure 2.1B). Nine of these mutations resided in 
the CARD domain, and one mutation was located in the Coiled-coil domain. 
Surprisingly, fourteen mutations occurred in the nineteen-residue region located 
between the CARD and Coiled-coil domains (Figure 2.1B and 2.1C).  This region of 
CARD11 has not been extensively characterized in previous studies. The high 
density of gain-of-function mutations between residues 112 and 130 defines this 
region as a functional domain that negatively regulates CARD11 activity. We refer to 
this region as the LATCH domain. 
 The specific activity of each variant that emerged from the screen was first 
determined by titrating its expression in the Igκ2-IFN-LUC reporter assay in 
HEK293T cells.  At equivalent levels of protein expression, the collection of variants 
displayed activities that were between 2.3- and 31-fold more active than wild-type 
CARD11 (see Figure 2.2A, 2.2B for example titrations and Table 2.1). For 
comparison, an ID-deleted variant, CARD11 ΔID, was 43.6 fold more active than wild 
type under these conditions.  The collection of variants displayed similar relative 
23 
 
potencies when expressed in a transient transfection assay in CARD11-deficient 
Jurkat T cells (Figure 2.2C, 2.2D and Table 2.1), indicating hyperactivity in both 
lymphoid and non-lymphoid cells.  The most potent mutations were distributed 
between the CARD and LATCH domains, and included C49Y and F97Y in the CARD 
domain, and G123D, V119E, and G126D in the LATCH domain.  Many of the 
mutations had effects on CARD11 activity that were comparable to or greater than 
those described previously for the F123I and L225LI mutations found in human 
DLBCL, which were found to increase specific activity by 12.6 and 28.1-fold in 
previous studies (21).  We note that the numbering scheme used previously (21, 28) 
to describe F123I and L225LI was based on a human CARD11 sequence that did not 
account for seven N-terminal residues; F123 and L225 correspond to F130 and 
L232 in our numbering scheme for murine CARD11 (11). 
 
Gain-of function mutations confer a selective ability to associate with Bcl10 
 We next determined whether the gain-of-function mutations conferred an 
enhanced ability for CARD11 to interact with the signaling cofactors that have been 
previously shown to associate with CARD11 in a signal-dependent and ID-regulated 
manner (13).  We co-expressed each variant with FLAG-tagged Bcl10 in HEK293T 
cells and assessed the degree to which each mutant co-immunoprecipitated with 
Bcl10, using wild-type CARD11 and the CARD11 ΔID as negative and positive 
controls, respectively. Eighteen of the gain-of-function mutants displayed enhanced 
abilities to associate with Bcl10 in this assay, as compared to wild-type CARD11 
(Figure 2.3 and Table 2.1).  The relative ability to associate with Bcl10 roughly 
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correlated with the ability of each variant to activate NF-κB, especially in Jurkat T 
cells (Table 2.1).  For example, the mutations that had the strongest effect on Bcl10 
association, C49Y, F97Y, G123D, G126D, and V119E, were the same mutations that 
elicited the greatest enhancements of activity in the Igκ2-IFN-LUC reporter assay. 
Five mutants did not display any enhanced association with Bcl10 (H31L, M32K, 
T112I, T117A, and E122D), and these were among the weakest gain-of-function 
mutants for NF-κB activation in Jurkat T cells. These data clearly indicate that most 
gain-of-function mutations identified enhance Bcl10 association with CARD11. In 
addition, the results reveal that the LATCH domain plays a critical role in controlling 
the CARD11:Bcl10 interaction. 
 We also tested whether the gain-of-function mutants affected the association 
of CARD11 with TAK1, TRAF6, Caspase-8, or IKKγ in similar immunoprecipitation 
studies. Interestingly, none of the mutations enhanced the interaction with any of 
these proteins (data not shown), indicating a selective effect on the Bcl10:CARD11 
interaction.  The F123I and L225LI mutations found in human DLBCL have the same 
cofactor-selective effect on Bcl10 association (21).  Since mutation of fourteen out of 
nineteen residues in the LATCH domain had no effect in these assays, the results 
suggest that the LATCH domain does not control the interaction between CARD11 
and TAK1, TRAF6, Caspase-8, or IKKγ. 
 MALT1 directly associates with Bcl10 and can be recruited to the F123I and 
L225LI mutants in a Bcl10-dependent manner (21).  We found that none of the gain-
of-function mutations identified in the CARD or LATCH domains was able to confer 
detectable binding to MALT1 in immunoprecipitation studies in the absence of co-
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expressed Bcl10 (data not shown). We then tested four of the most active variants 
isolated in our screen to see if their mutations would allow Bcl10-dependent 
recruitment of MALT1 to CARD11.  As shown in Figure 2.4, FLAG-tagged MALT1 
could associate with the C49Y, F97Y, G123D, and G126D mutants when coexpressed 
in the presence of Bcl10, indicating that when bound to these mutants, Bcl10 is 
competent to recruit MALT1 to CARD11.  The effect of these mutations in this assay 
was comparable to that achieved by deletion of the ID. 
 
Gain-of function mutations perturb ID binding 
We have previously shown that the ID can associate in trans with the 
CARD11 ΔID construct in a manner that depends upon the CARD and Coiled-coil 
domain (13).  The F123I and L225LI oncogenic mutations found in human DLBCL 
reduce this association (21). To test the hypothesis that the gain-of-function 
mutations we isolated also disrupt ID binding we introduced each mutation into the 
context of the CARD11 ΔID construct and tested for their association with an ID-GST 
fusion protein under subsaturating conditions after expression in HEK293T cells.  
All 24 mutations reduced ID binding in trans in this assay (Figure 2.5 and Table 2.1) 
to varying degrees.  The strongest effects on ID binding were observed for 12 
mutants, 7 in the CARD domain (H31L, M32K, C49Y, K50M, N62Y, E93D, F97Y), and 
5 in the LATCH domain (T112I, R113Q, R114I, I118V, G123D), all of which displayed 
0-20% of the ID binding observed with the unmutated CARD11 ΔID.  These data are 
consistent with the prediction that gain-of-function mutations would impact the 
ability of the ID to participate in intramolecular inhibitory interactions. In addition, 
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the results reveal a previously unappreciated role for the LATCH domain in 
promoting ID binding. 
 
Hyperactive mutants require Bcl10, MALT1, TRAF6, and TAK1 for signaling to 
NF-κB 
Bcl10 is a required signaling cofactor for CARD11 in normal antigen receptor 
signaling (38) as well as for the F123I and L225LI oncogenic variants that signal 
independently of receptor triggering (21).  To confirm that the novel hyperactive 
mutants we identified also require Bcl10 for signaling to NF-κB, we tested the effect 
of knocking down Bcl10 on their activities in the Igκ2-IFN-LUC reporter assay in 
HEK293T cells. As expected, the activity of all mutants, regardless of their potency, 
was severely diminished as a result of Bcl10 deficiency (Figure 2.6 and data not 
shown). 
 For several of the most active variants, we also tested the dependence of 
their signaling activity on MALT1, TRAF6, and TAK1.  We compared the activities of 
the G123D, F97Y, C49Y, G126D, V119E, and Y98F in Jurkat T cell lines that stably 
expressed a control short hairpin RNA (KD-NT) or one that targeted MALT1 (KD-
MALT1) or TRAF6 (KD-TRAF6). As shown in Figure 2.7, the 75% and >75% 
reduction in MALT1 and TRAF6 levels, respectively, reduced the apparent activity of 
all of the mutants tested, as assessed in the Igκ2-IFN-LUC reporter assay (Figure 
2.7A to 2.7C).  To test the requirement for TAK1, we treated Jurkat T cells with 5Z-7-
oxozeaenol, a specific inhibitor of TAK1 (39, 40), after transient expression of these 
variants in the reporter assay. As shown in Figure 2.7D, the signaling activity of all 
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variants tested was inhibited by 5Z-7-oxozeaenol to a level similar to that observed 
after ΔID expression or treatment with anti-CD3/anti-CD28 antibodies. 
 
Gain-of-function variants induce K63-linked ubiquitination of Bcl10 and the 
association of Ubn(K63)-Bcl10 with IKKγ  
 The K63-linked ubiquitination of the CARD domain of Bcl10 on K31 and K63 
is a required step downstream of CARD11 action in the TCR signaling pathway to 
NF-κB (22).  Furthermore, we demonstrated that the F123I and L225LI oncogenic 
variants fail to activate NF-κB in the presence of a Bcl10 mutant containing arginine 
substitutions at K31 and K63 (21), suggesting that F123I and L225LI also depend 
upon Bcl10 ubiquitination for their dysregulated signaling.  To test whether gain-of-
function mutations in the CARD and LATCH domains spontaneously induce the K63-
linked ubiquitination of Bcl10, we used retroviral-mediated infection to establish a 
panel of Jurkat T cell lines that stably expressed twelve variants with a range of 
specific activities.  Five of these variants harbored mutations in the CARD domain 
(M32K, C49Y, N62Y, E93D, and Y98F) while 7 contained LATCH domain mutations 
(T112I, E121G, E122D, G123D, G126D, L127I, and F130Y).  To confirm that each 
variant spontaneously activated NF-κB after stable expression, we transfected each 
line with the Igκ2-IFN-LUC reporter and compared the fold induction to that 
observed with a control line expressing wild-type CARD11 in the absence and 
presence of PMA/ionomycin treatment, which mimics signaling downstream of the 
TCR.  As shown in Figure 2.8A, stable expression of wild-type CARD11 did not 
induce appreciable reporter activation, while PMA/Iono treatment of this line 
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resulted in 27-fold reporter activation.  As expected, many of the gain-of-function 
variants spontaneously activated the reporter at levels of expression comparable to 
the wild-type control (Figure 2.8A).  The C49Y and G123D variants were the most 
potent, achieving levels of activation similar to that observed with PMA/Iono 
treatment of the control line.  The activity of the stably expressed gain-of-function 
variants also led, as expected, to the spontaneous induction of nuclear NF-κB DNA 
binding activity, as revealed by EMSA analysis of nuclear extracts using a consensus 
κB site DNA probe (Figure 2.8B).   The extent of induction of NF-κB DNA-binding 
activity closely correlated with the activities exhibited in the reporter assay. 
 To probe for K63-linked ubiquitination of Bcl10, Bcl10 was 
immunoprecipitated from denatured cell lysates from these lines (22), and assessed 
for the presence of conjugated ubiquitin using K63-linkage-specific antibodies.  K63-
linked ubiquitinated Bcl10 (Ubn(K63)-Bcl10) was detected in the presence of ten of 
the variants, but not in the presence of the two weakest variants (Figure 2.8C and 
2.8E). The levels of Ubn(K63)-Bcl10 correlated remarkably well with the specific 
activities displayed in the NF-κB reporter and EMSA assays.  In addition, the levels 
of unconjugated Bcl10 inversely correlated with the activity of each variant (Figure 
2.8C). 
 Since Ubn(K63)-Bcl10 has been shown to associate with IKKγ during TCR 
signaling (22), we immunoprecipitated IKKγ from lysates from these stable lines 
and probed for the presence of associated Ubn(K63)-Bcl10. Indeed, we observed 
that Ubn(K63)-Bcl10 associated with IKKγ to an extent that correlated with the 
degree of NF-κB activation in the reporter and EMSA assays (Figure 2.8D and 2.8F).   
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These data indicate that several of the gain-of-function variants induce K63-linked 
ubiquitination of Bcl10 and the association of Ubn(K63)-Bcl10 with IKKγ, even in the 
absence of antigen receptor engagement or signaling upstream of CARD11. In 
addition, they strongly suggest that residues in both the CARD (C49, N62, E93, and 
Y98) and LATCH (T112, E122, G123, G126, L127, and F130) domains function to 
prevent spontaneous Bcl10 ubiquitination and the association of Ubn(K63)-Bcl10 
with IKKγ, two critical CARD11-dependent steps in IKK complex activation by 
antigen receptor signaling. 
 
Gain-of-function mutations in the CARD and LATCH domains can promote the 
growth of a human DLBCL line in culture 
The OCI-Ly3 cell line, which is representative of the ABC subtype of DLBCL 
harbors the L244P oncogenic variant of CARD11 and relies on CARD11-dependent 
signaling to NF-κB for survival and proliferation in culture (28). We adapted an 
assay originally developed by Lenz et al. (28) to assess the potential for hyperactive 
CARD11 variants to substitute for the L244P variant in this OCI-Ly3 line.  We stably 
introduced ten murine CARD11 variants into the OCI-Ly3 line by retroviral 
transduction, and then superinfected the stable lines with a retrovirus that 
coexpressed GFP with an shRNA that could target the endogenous human L244P 
CARD11 mRNA by RNA interference (shC11). As previously demonstrated (28), the 
parental OCI-Ly3 line was highly sensitive to CARD11 L244P knockdown, as 
indicated by the 56% loss of GFP+ cells over 18 days in culture (Figure 2.9A).  The 
presence of the hairpin-resistant murine L244P oncogenic mutant served as a 
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positive control for the assay and rescued a significant fraction of the cells, resulting 
in an increased survival of GFP+ cells over the same time course (Figure 2.9A).  
Among the nine gain-of-function mutants tested, the G123D, G126D, C49Y, and 
L127I mutants showed the best abilities to rescue the OCI-Ly3 cells (Figure 2.9A).  
The E93D, Y98F and F130Y mutants also displayed significant rescue ability, while 
the T112I and N62Y mutants only conferred a slight cell survival advantage, as 
compared to the OCI-Ly3 parental control (Figure 2.9B). An assessment of the 
expression levels of the different hyperactive variants (Figure 2.9C) indicated that 
the level of the G123D variant was slightly higher than other variants, while those of 
L244P, N62Y, and T112I variants were slightly lower.  Analysis of GFP+ cells from 
four lines revealed that expression of the shC11 hairpin resulted in 50-60% 
reduction in endogenous CARD11 expression under the conditions of this 
experiment (Figure 2.9D).  Overall, there was a good correlation between the 
specific activities of the variants for rescue in this assay and their abilities to activate 
NF-κB when stably expressed in Jurkat T cells (Figure 2.8A), with the exception of 
the L127I mutant, which had greater relative OCI-Ly3 rescue activity than expected. 
The results indicate that gain-of-function mutations in both the CARD (C49Y, E93D, 
Y98F) and the LATCH (G123D, G126D, L127I, F130Y) domains can provide sufficient 
activity to promote the survival of human DLBCL-derived cells that depend on NF-







The central role that CARD11 serves in relaying signaling from the antigen 
receptor to NF-κB depends upon its signal-induced transition from a closed inactive 
state to an open active scaffold that can recruit signaling cofactors to activate the 
IKK complex. Previous studies established that this transition is regulated by the ID 
through intramolecular interactions involving the CARD and Coiled-coil domains 
(13), and that two DLBCL-associated oncogenic mutations achieve hyperactive 
signaling by disrupting ID-mediated autoinhibition (21). These findings led us to 
hypothesize that in addition to those described in the Coiled-coil domain, 
hyperactive mutations should occur in other domains of CARD11 involved in the ID-
mediated repression.  Our data confirms that this hypothesis is correct. The screen 
for gain-of-function CARD11 variants yielded several mutations in the CARD domain 
that disrupt ID binding, as we predicted.  Unexpectedly, the screen also identified a 
strikingly high density of mutations in the LATCH domain, a short nineteen-residue 
region between the CARD and Coiled-coil that clearly plays a requisite role in 
autoinhibition by the ID. 
 Mutations in both the CARD and LATCH domains resulted in the disruption of 
ID binding, the selective enhanced association with Bcl10, the spontaneous 
ubiquitination of Bcl10, and the subsequent activation of the IKK complex and NF-
κB (Figure 2.10). These mutants cause hyperactivity by the same mechanisms 
ascribed to the F123I and L225LI mutants that were identified in human DLBCL.  
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 The chief conclusion that emerges from our data is that the intramolecular 
regulation of CARD11 that allows for its signal-dependent activation by antigen 
receptor signaling also results in a vulnerability to mutation that can be exploited by 
lymphoid cancers to bypass normal controls and induce NF-κB and its pro-
proliferative and anti-apoptotic target genes.  
 All of the gain-of-function mutations in the CARD and LATCH domains reduce 
ID binding to the CARD11 ΔID variant in trans. The effects on ID binding likely 
account for the enhanced ability of eighteen of the mutants to associate with Bcl10.  
It is clear, however, that there is not an absolute quantitative correlation for all 
mutants between the positive effect on Bcl10 binding and the degree to which a 
mutation disrupted ID binding.  This is probably due to the fact that the ID and 
Bcl10 bind to partially overlapping determinants in the CARD-LATCH-Coiled-coil 
region such that some mutations that deleteriously affect ID binding may also 
partially interfere with Bcl10 association.  The net effect of such mutations would 
still be expected to increase Bcl10 association as compared to what would occur 
with the closed, inactive wild-type CARD11. 
 It is intriguing that among the gain-of-function mutations that emerged in the 
screen, eighteen of twenty-three increased Bcl10 binding and none appreciably 
increased the association of other signaling cofactors whose recruitment to CARD11 
is also controlled by the ID. This suggests that selectively enhancing Bcl10 
association with CARD11 is sufficient to initiate signaling, presumably by promoting 
the K63-linked ubiquitination of Bcl10.  It is important to point out, however, that 
the binding of other signaling cofactors that we did not examine, or that remain 
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unknown could also be affected by some or all of the mutations and may be 
important in determining signaling output. This possibility is suggested by 
differences in the specific activity of some mutants in the NF-κB reporter assay that 
otherwise display very similar abilities to bind Bcl10, and by the five mutants that 
did not enhance Bcl10 binding in the co-immunoprecipitation assay.  
 The enhanced association of Bcl10 with CARD11 that is induced by most of 
the mutations appears to promote the same K63-linked ubiquitination of Bcl10 that 
transiently occurs during normal antigen receptor signaling and that licenses Bcl10 
for its action on the IKK complex through its association with IKKγ. For the twelve 
mutants analyzed after stable expression in Jurkat T cells, there was a good 
correlation between their enhancements in Bcl10 binding and the levels of 
Ubn(K63)-Bcl10 that were spontaneously produced in these cells. The ability of 
CARD11 mutations to elicit Bcl10 ubiquitination suggests that during normal 
antigen receptor signaling, there are no CARD11-independent signaling events 
upstream of CARD11 activation that are required to induce this modification of 
Bcl10. The hyperactive CARD11 mutants must be sufficient to directly or indirectly 
promote the association between Bcl10 and the as yet unidentified E3 ligase that 
mediates conjugation. The levels of Ubn(K63)-Bcl10 produced as a result of 
hyperactive variant expression correlated well with the observed binding of 
endogenous Ubn(K63)-Bcl10 to IKKγ, and with the relative degree of NF-κB 
activation.  These data emphasize the importance of K63-linked polyubiquitinated 
Bcl10 as a signaling intermediate in this pathway that can dictate the extent of 
signal output.  During normal antigen receptor signaling, polyubiquitinated Bcl10 is 
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produced only transiently (22), and is removed by degradative mechanisms that 
serve to terminate signaling (41–43).  In cells stably expressing the most active 
hyperactive variants, we readily detect a steady state level of Ubn(K63)-Bcl10 
indicating that its production must override these normal negative feedback 
mechanisms.  It is clear that in order to fully understand how both normal and 
dysregulated CARD11 signaling occurs, further studies are necessary to identify the 
E3 ligase that ubiquitinates Bcl10 through K63-linkages, explain how the association 
with CARD11 promotes this modification, and elucidate how exactly Ubn(K63)-
Bcl10 activates IKK kinase activity. 
 The six highly active variants tested also required MALT1, TRAF6, and TAK1 
for signaling to NF-κB.  These factors have been shown by others to be required for 
IKK kinase induction downstream of antigen receptor engagement. MALT1 is 
required for K63-linked ubiquitination of Bcl10 (22), and has also been implicated 
in K63-linked ubiquitination of IKKγ (44). TRAF6 also contributes to IKKγ K63-
linked ubiquitination (30), but does not appear to be required for the induction of 
K63-linked ubiquitination of Bcl10 (data shown in Chapter III).  TAK1 has been 
shown to mediate IKK kinase subunit phosphorylation during signaling (40).  Our 
data indicate that the activities of these factors must function in concert with 
Ubn(K63)-Bcl10 to effect maximal NF-κB activation downstream of hyperactive 
CARD11 variants. 
 Most of the hyperactive variants that we tested had enough enhanced activity 
to promote the proliferation and survival of the ABC DLBCL-derived OCI-Ly3 line in 
culture.  There was a good correlation between the ability to activate NF-κB after 
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stable expression in Jurkat T cells and the ability to protect OCI-Ly3 cells from 
apoptosis in culture. However, the L127I mutant had more potential to enhance the 
survival of OCI-Ly3 cells than we would have expected based upon its relative 
activity after stable expression in Jurkat T cells.  This observation may suggest that 
cell-type specific aspects of the cellular environment in lymphoma can influence the 
potency of hyperactive CARD11 variants, such as the absence or presence of 
proteins that modify CARD11 signaling to NF-κB and whose functional interaction 
with CARD11 could be affected by some mutations and not others.  The T112I and 
N62Y mutants did not provide much protection to OCI-Ly3 cells, but their enhanced 
abilities to activate NF-κB may be sufficient to contribute to the growth and survival 
of lymphoid cancers in other settings that have sustained other genetic alterations 
that could cooperate with weaker CARD11 mutants. 
 While this work was in progress, several studies reported the presence of 
CARD11 mutations in the CARD and LATCH domains in human biopsies of DLBCL.  
Six of these are identical to mutations that we isolated in our screen, including C49Y 
(45), C49S (46), E93D (46), F115L (46, 47), G123D (48), and G126D (49).  Four 
other reported mutations occur at the same position as those we found in our 
screen, but mutate to a different residue, including R114I (46), F115I (47), T117P 
(46), and F130V (49).  Although these studies did not demonstrate a functional 
effect of the mutations in the context of the cancers in which they were sequenced, 
our data provide a mechanistic characterization that can explain how the 
substitutions could lead to dysregulated NF-κB activity and promote proliferation 
and survival.  
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 Our quantitative high-throughput screen could be easily expanded to detect 
other gain-of-function mutations in other domains of CARD11 including the Coiled-
coil domain.  A database of such mutations would provide functional insight that 
would complement the catalog of cancer biopsy-associated CARD11 mutations that 
is likely to grow as more samples are surveyed.  The screening methodology is 
modular, making it straightforward to substitute the protein that undergoes 
mutation and screening and therefore easily adaptable to the analysis of other 
proteins that incur gain-of-function mutations in NF-κB-dependent cancers, such as 
MyD88, CD79A, or CD79B (18). With the substitution of the NF-κB reporter with 
that of another transcription factor the screen could readily be applied to molecules 
that influence the activity of other gene regulators that promote tumorigenesis in 


































Figure 2.1:  A quantitative signaling screen identifies gain-of-function 
mutations in the CARD and LATCH domains of CARD11. 
(A) Example of primary screening in which four clones scored as positives.  Clones 1, 
5, 34, and 36 encoded C49Y, V119E, H129Y and T117A mutations respectively.   
(B) Summary of all mutations identified in the primary sequence at the N-terminus 
of CARD11.  CARD domain residues are depicted in black, LATCH domain residues in 
blue, and the N-terminal end of the Coiled-coil domain in gray.   
(C) Model for CARD11 in the closed inactive state. CARD11 is depicted as a dimer for 



















Figure 2.2:  Relative Specific Activity of CARD11 variants in HEK293T and 
Jurkat T cells.  
(A-B) HEK293T cells were transfected with 20 ng of Igκ2-IFN-LUC and 6 ng of CSK-
LacZ in the presence of the indicated amounts (in ng) of expression vectors for the 
indicated myc-tagged CARD11 variants. The panel below each titration displays 
western blots of corresponding lysates probed with anti-myc primary antibody to 
indicate the relative expression level of each variant. β-galactosidase activity, driven 
by CSK-LacZ, was used to normalize luciferase activity and to calculate equivalent 
amounts of transfected cell-lysate for western analysis.  
(C-D) Jurkat T cells in which CARD11 was stably knocked down (KD-CARD11) were 
transfected with 200 ng of CSK-LacZ and 1500 of ng Igκ2-IFN-LUC in the presence of 
50-90 ng of expression vectors for the indicated variants.  Vector quantities were 
adjusted to achieve equivalent protein expression levels for each variant, using the 









Figure 2.3:  Mutations in the CARD and LATCH domains enhance the ability of 
CARD11 to associate with Bcl10. 
(A-F) HEK293T cells were transfected with 70-240 ng of expression vectors for the 
indicated myc-CARD11 variants and 70-225 ng of FLAG-Bcl10, as indicated. Anti-
FLAG immunoprecipitations were performed as described in Experimental 
























Figure 2.4:  Gain-of-function mutations enhance Bcl10-mediated association of 
MALT1 with CARD11. 
(A-B) HEK293T cells were transfected with 400-700 ng of expression vectors for the 
indicated myc-CARD11 variants, 500-800 ng of FLAG-MALT1 and 300-500 ng of 
untagged Bcl10, as indicated. Anti-FLAG immunoprecipitations were performed as 
described in Experimental Procedures and analyzed by western blot with the 
























Figure 2.5:  Mutations in the CARD and LATCH domains disrupt ID binding in 
trans. 
(A-D) HEK293T cells were transfected with 800-2000 ng of expression vectors for 
the indicated CARD11 ΔID variants or with 2000 ng or 1500 ng of expression 
vectors for ID-GST or GST, respectively. Lysates were mixed as indicated, incubated, 
and glutathione-sepharose pulldowns were performed as described in Experimental 


































Figure 2.6:  Hyperactive CARD11 variants require Bcl10 for NF-κB activation. 
(A-D) HEK293T cells stably expressing a shRNA that targets either Bcl10 (KD-Bcl10) 
or GFP (KD-GFP) as control were transfected with 20 ng of Igκ2-IFN-LUC, 6 ng of 
CSK-LacZ , and 8-100 ng of expression vectors for the indicated myc-tagged CARD11 
variants. The panels below each assay display western blots of corresponding 
lysates probed with anti-myc or anti-Bcl10 primary antibody to indicate the relative 
expression level of each variant and Bcl10 in each sample. β-galactosidase activity, 
driven by CSK-LacZ, was used to normalize luciferase activity and to calculate 





















Figure 2.7:  Hyperactive variants require MALT1, TRAF6, and TAK1 for NF-κB 
activation. 
(A, B) Jurkat T cells stably expressing hairpins that target MALT1 (KD-MALT1) or 
TRAF6 (KD-TRAF6), or a control hairpin (KD-NT), were transfected with 200 ng of 
CSK-LacZ and 1500 ng of Igκ2-IFN-LUC in the presence of the indicated amounts of 
expression vectors for the indicated CARD11 variants and assayed as described in 
Experimental Procedures.  
(C) Lysates from KD-MALT1 and KD-TRAF6 Jurkat T cell lines were assayed by 
western blot with the indicated primary antibodies.  
(D) Jurkat T cells were transfected with 200 ng of CSK-LacZ and 1500 ng of Igκ2-IFN-
LUC in the presence of 100 ng of expression vectors for the indicated CARD11 
variants.  Either DMSO vehicle (-) or 500 nM 5Z-7-oxozeaenol (+) was added to each 
sample as indicated every 12 hours after transfection for a total of 3 doses.  The 
indicated samples were stimulated with 1 μg/ml anti-CD3/anti-CD28 crosslinking in 
















Figure 2.8:  Hyperactive CARD11 variants induce K63-linked Ubiquitination of 
Bcl10 and the association of Ubn(K63)-Bcl10 with IKKγ. 
(A) Jurkat T cell lines stably expressing the indicated CARD11 variants fused to 
mCherry were generated by retroviral infection and transiently transfected with 
200 ng of CSK-LacZ and 1500 ng of Igκ2-IFN-LUC and assayed as described in 
Experimental Procedures.  The line expressing wild-type CARD11 was treated with 
50 ng/ml PMA and 1 μM ionomocyin for 4 hours as indicated.   
(B) Electrophoretic Mobility Shift Assays were performed using 3 μg of nuclear 
extracts from the stably expressing Jurkat T cell lines in (A) and a 32P-labelled DNA 
fragment containing a consensus κB site.  The line expressing wild-type CARD11 
was treated with 50 ng/ml PMA and 1 μM ionomycin for 30 minutes as indicated.  
(C) Immunoprecipitations were performed using denatured lysates from the stably 
expressing Jurkat T cell lines in (A) using anti-Bcl10 antibodies and analyzed by 
western blot with anti-Ubiquitin (K63-linkage specific), anti-Bcl10, or anti-myc 
primary antibodies as indicated.  The line expressing wild-type CARD11 was treated 
with 50 ng/ml PMA and 1 μM ionomocyin for 20 minutes as indicated.  
(D) Immunoprecipitations were performed using lysates from the stably expressing 
Jurkat T cell lines in (A) using anti-IKKγ antibodies and analyzed by western blot 
with anti-Bcl10, or anti-IKKγ primary antibodies as indicated.  The line expressing 
wild-type CARD11 was treated with 50 ng/ml PMA and 1 μM ionomocyin for 20 
minutes as indicated. The relative expression level of CARD11 variants in this 
experiment is also indicated in the anti-myc western blot in (C) since the same cell 
lines were used in (C) and (D).  
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(E) Quantitation of the levels of Bcl10-Ub detected in each sample in (C), divided by 
the levels of unconjugated Bcl10, normalized to the ratio observed in the WT sample. 
(F) Quantitation of the levels of Bcl10-Ub detected in the IP with IKKγ in (D), divided 


























Figure 2.9:  CARD11 variants containing gain-of-function mutations in the 
CARD and LATCH domains can promote the survival of OCI-Ly3 human DLBCL-
derived cells. 
(A-B) OCI-Ly3 cells stably expressing the indicated CARD11 variants were 
generated by retroviral infection as described in Experimental Procedures. Each line 
was superinfected with a retrovirus that coexpresses GFP and a shRNA that targets 
the endogenous human CARD11 mRNA (shC11). The percent GFP+ cells were 
normalized to the percentage observed on Day 3 after infection.  The survival curves 
for the parental OCI-Ly3 line and the line rescued with the L244P positive control 
are depicted in each panel for ease of comparison.   
(C) Lysates from the OCI-Ly3 lines stably expressing the indicated CARD11 variants 
were analyzed by western blot using anti-myc and anti-IKKα antibodies as indicated 
to reveal the relative expression level of each variant.  
(D) OCI-Ly3 cells stably expressing the indicated myc-CARD11-mCherry variants 
were infected with a retrovirus coexpressing GFP with either a hairpin targeting 
endogenous human CARD11 (shC11) or a control hairpin (shNT). Seven days after 
infection, GFP+ cells were isolated by FACS and lysates were analyzed by western 

































Figure 2.10:  Model depicting how gain-of-function mutations in the CARD, 
























































Identification of Putative Protein Regulators of the CARD11 














CARD11-dependent antigen receptor signaling to NF-κB, essential for normal 
lymphocyte activation, is dysregulated in human diffuse large B cell lymphoma by 
mutations that exist within the CARD, LATCH, and the Coiled-coil domains.  
Oncogenic CARD11 mutations evolve to bypass upstream signaling requirements 
and spontaneously induce K63-linked polyubiquitination of Bcl10, a critical 
signaling intermediate in IKK complex activation.  In this report, we identify two 
CARD11 signaling cofactors, TRAF2 and TAK1, whose functions are required for the 
induction of K63-linked ubiquitination of Bcl10 and the hyperactive signaling of 
oncogenic CARD11 mutations.  Furthermore, when combining the most active 
CARD11 missense mutations in both the CARD and the Coiled-coil domain, we 
identify a super mutant that synergizes the signaling activities of two oncogenic 
CARD11 missense mutations, C49Y and L251P, both of which have been identified in 
human DLBCL patients, although the signaling mechanism of L251P remains poorly 
understood.  The signaling capacity of this super mutant distinctly differs from ΔID 
in that its activity no longer depends on the presence of the L4 domain and that its 
hyperactivity is not completely abolished in the absence of the L3, SH3 or GUK 
domain.  Similar to C49Y, this super mutant selectively enhances its association with 
Bcl10 and MALT1, but not the other signaling cofactors tested.  Protein complex 
purification of this super mutant along with mass spectrometry analysis identifies 
several CARD11 signaling cofactors including Bcl10, MALT1, IKKγ, CK1α and STUB1, 
in addition to a list of putative cofactors such as USP7, UBE3C, CKIIα, IGBP1, 14-3-3ε 
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and EFHD2.  Our results identify critical components during the assembly of Bcl10 
ubiquitination, a novel super-hyperactive CARD11 mutant for further mechanistic 
studies, and several putative protein regulators of the CARD11 scaffold complex that 
are potentially dysregulated by oncogenic CARD11 mutations. 
 
Introduction 
In Chapter II, we identified and characterized a collection of hyperactive and 
potentially oncogenic CARD11 mutations located within the CARD and the LATCH 
domain that can signal to activate NF-κB even in the absence of antigen receptor 
signaling.  In addition to disrupting the ID autoinhibition against the CARD and the 
Coiled-coil domains, these mutations specifically enhanced the ability of CARD11 to 
associate with Bcl10 and spontaneously induce K63-linked polyubiquitination of 
Bcl10, a signaling step required for normal TCR signaling (22).  Although none of 
these mutations enhances the ability of CARD11 to recruit other signaling cofactors 
whose association with CARD11 are also controlled by the ID, it is possible that the 
binding of other signaling cofactors that we did not examine, or that remain 
unknown could also be affected by some of the mutations and may be important in 
determining signaling output.  Potential candidate cofactors that were not examined 
by our previous studies but have been shown by the other studies to associate or 
regulate the CARD11-Bcl10-MALT1 (CBM) complex include CK1α (50), TRAF2 (45, 
51), HPK1 (52), PP2A (53), Akt (54), CaMKII (55, 56), CSN (57), MIB2 (58), STUB1 
(59) and GAKIN (29). 
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 During regulated antigen receptor signaling, K63-linked polyubiquitinated 
Bcl10 is produced only transiently (22), and is rapidly removed by degradative 
mechanisms that serve to terminate signaling (41–43).  In cells stably expressing the 
most active hyperactive variants, we readily detect a steady state level of Ubn(K63)-
Bcl10 (see Chapter II), indicating that its production must override these normal 
negative feedback mechanisms.  These hyperactive CARD11 mutants must be 
sufficient to directly or indirectly promote the association between Bcl10 and the as 
yet unidentified E3 ligase that mediates conjugation.  In order to fully understand 
how both normal and dysregulated CARD11 signaling occurs, further studies are 
necessary to identify the E3 ligase that ubiquitinates Bcl10 through K63-linkages, 
explain how the association with CARD11 promotes this modification, and elucidate 
how exactly Ubn(K63)-Bcl10 activates IKK kinase activity.  Several E3 ubiquitin 
ligases (such as TRAF6, TRAF2, MIB2 and STUB1) have been shown to get recruited 
to CARD11 or Bcl10 upon antigen receptor signaling, however, there is not yet any 
evidence to support that any of these E3 ligases serves specifically to conjugate K63-
linked polyubiquitination on Bcl10. 
 The CARD11 variant ΔID has been considered to be the most active mutant, 
with enhanced ability to recruit multiple signaling cofactors including Bcl10, MALT1, 
TRAF6, TAK1, IKKγ, and Caspase-8 (13), in the absence of the ID autoinhibition.  As 
shown in Table 2.1, ΔID confers the highest specific activity in both HEK293T and 
Jurkat T cells when compared to the other hyperactive CARD11 variants.  The ability 
of ΔID to enhance Bcl10 recruitment is also the strongest among the other variants.  
These data had led us to believe that the ΔID variant represents the maximum 
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signaling capacity of CARD11.  However, a rare double mutant (F115L+I118V) that 
emerged unexpectedly during our previous study provided data to challenge this 
belief.  With a similar specific activity as the ΔID, this double mutant enhances Bcl10 
binding in the same immunoprecipitation assay (Figure 2.3) to an extent that 
exceeds ΔID by 30 to 50%.  This is the first time that we observed a synergistic effect 
created by the fusion of two relatively less hyperactive CARD11 variants.  This 
accidental discovery led us to wonder whether we could generate even more 
powerful double, triple or quadruple mutants by combining some of the most active 
CARD11 variants that have been identified and characterized in previous studies. 
In this report, we address these issues by identifying signaling cofactors that 
are required for the K63-linked polyubiquitination of Bcl10, a novel super-
hyperactive CARD11 variant that signals to NF-κB distinctly from ΔID, and several 
putative protein regulators of the CBM complex that are potentially important for 




MALT1-, TRAF6-, and TRAF2-deficient Jurkat T cell lines 
 To generate the KD-NT, KD-MALT1, KD-TRAF6, and KD-TRAF2 Jurkat T cell 
lines, pLKO.1-based lentiviruses were constructed to express either shNT (Sigma 
SHC002; Sense sequence: 5’-CAACAAGATGAAGAGCACCAA-3’; loop sequence: 5’-
CTCGAG-3’), shM1 ((13); Sense sequence: 5’-CCTCACTACCAGTGGTTCAAA-3’; loop 
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sequence: 5’-CTCGAG-3’), shT6 ((30); Sense sequence: 5’-
CCACGAAGAGATAATGGAT-3’; loop sequence: 5’-TTCAAGAGA-3’), or shT2 ((60); 
Sense sequence: 5’-GATGTGTCTGCGTATCTACCT-3’; loop sequence: 5’-CTCGAG-3’).  
Lentiviral packaging, infection condition and puromycin selection were performed 
as described previously (61).  Knockdown was assessed by western blot using anti-
MALT1 (catalog# 1664-1; Epitomics), anti-TRAF6 (sc-7221; Santa Cruz), and anti-
TRAF2 (sc-876; Santa Cruz) antibodies. 
 
Endogenous Bcl10 immunoprecipitations in Jurkat T cell lines 
Wild-type Jurkat or Jurkat T cell line stably expressing pLKO.1-based shNT, 
shM1, shT6, or shT2 was stimulated with 50 ng/ml PMA (Sigma) and 1 μM 
ionomycin (Sigma) for 20 min at 37°C.  Cells (108 per sample) were then incubated 
in an ice water bath for 5 min, spun at 423 x g for 10 min at 4°C, and lysed in a lysis 
buffer as described previously (61).  Cell lysates were precleared twice with 20 µl 
bed volume of Protein A-Sepharose (Sigma P9424) for 1 to 2 h at 4°C with rotation.  
To analyze Bcl10 ubiquitination, the precleared lysates were treated as described 
previously (61).  (5Z)-7-oxozeaenol was obtained from Calbiochem (product code 
499610).  Jurkat T cells were pretreated with either DMSO vehicle (-) or 2 μM (5Z)-
7-oxozeaenol (5Z-7-o) (+) for 30 min prior to PMA/ionomycin treatment and lysis 
as described above.  Western blots were analyzed using anti-Ub-K63 (14-6077-82; 
eBioscience), anti-Bcl10 (sc-5273; Santa Cruz), anti-MALT1 (catalog# 1664-1; 




Reporter assays of Jurkat T cells 
Jurkat T cells were transfected with Igκ2-IFN-LUC and CSK-LacZ as described 
previously (13) using 30-280 ng of expression construct for each CARD11 variant. 
 
Immunoprecipitations in HEK293T cells 
One day prior to transfection, 5x105 HEK293T cells were plated in each well 
of a six-well plate.  A total of 2 μg DNA per well was transfected using the calcium 
phosphate method.  The medium was changed approximately 24 h posttransfection, 
and the cells were harvested 42 to 46 h posttransfection.  Cells were lysed in 500 μl 
of immunoprecipitation lysis buffer (IPLB) and debris was removed as described 
previously (13).  20 μl of cell lysate was saved for western blot analysis and 450 μl 
was incubated with 1 μg of anti-FLAG antibody (Sigma F7425) for 2 h at 4°C with 
rotation.  10 μl bed volume of protein G-Sepharose 4 Fast Flow (GE Healthcare) was 
added and incubated for 2 h at 4°C with rotation.  The resulting immunocomplex 
was washed with IPLB four times for 5 min at 4°C with rotation, eluted twice, pooled, 
and resolved for western blot analysis as described previously (21) using anti-myc 
(sc-40; Santa Cruz), anti-FLAG (M2; Sigma F1804), and anti-Bcl10 (sc-5273; Santa 
Cruz) antibodies.  
 
Biotin pulldowns and elutions 
 CARD11 variants with C-terminal Biotag, a biotin acceptor peptide, was 
constructed as described previously (62).  One day prior to transfection, 15x106 or 
150x106 HEK293T cells were plated in two or twenty 15-cm tissue culture plates 
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per condition.  A total of 30 μg DNA per plate was transfected using the calcium 
phosphate method.  The medium was changed and 50 μM of biotin was added 
approximately 24 h posttransfection, and the cells were harvested 42 to 46 h 
posttransfection.  Cells per two 15-cm plates were trypsinized, pooled, washed 
twice with warm PBS, and lysed in 1.2 ml IPLB for 20 min at 4°C.  Cell debris was 
removed by centrifugation at 16,000 xg for 10 min.  1.3 ml of cell lysate was 
incubated with 100 μl bed volume of NeutrAvidin Agarose Resins (Thermo Scientific) 
for 2 h at 4°C with rotation.  The Neutravidin Beads were washed with IPLB four 
times for 5 min at 4°C with rotation and eluted sequentially for 30 min at room 
temperature with: 1) 1 ml elution buffer containing 10 mM TRIS (pH 7.4), 150 mM 
NaCl and protease inhibitor cocktail (PIC, Sigma P8340); 2) 1 ml elution buffer 
containing 10 mM TRIS (pH 7.4), 300 mM NaCl and PIC; 3) 1 ml elution buffer 
containing 10 mM TRIS (pH 7.4), 300 mM NaCl, 0.06% SDS, 50 mM DTT and PIC.  
Each elution was concentrated with Amicon Ultra 3K device (Millipore) to a final 
volume of approximately 60 μl and resolved by 10% SDS-PAGE. 
 
Protein staining and mass spectrometry 
 Protein bands resolved on SDS-PAGE gel were analyzed by Silver Stain Plus 
Kit (BioRad) or homemade colloidal blue stain (for mass spectrometry) prepared as 
described previously (63).  In-gel digestion, micro-capillary LC/MS/MS analysis, 
protein database searching, and data analysis were performed by Taplin Mass 





TRAF2 and TAK1 are required for K63-linked ubiquitination of Bcl10 
 Since RNAi of TRAF6, TRAF2, and TAK1 have been shown previously (30) to 
inhibit TCR-induced IKK activation and IL-2 production in T cells, we wondered 
whether the absence of these CARD11 signaling cofactors could also inhibit the 
induction of K63-linked ubiquitination of Bcl10, a critical signaling intermediate 
required for TCR-induced IKK activation.  To probe for Ubn(K63)-Bcl10, Bcl10 was 
immunoprecipitated from denatured cell lysates of wild-type or pLKO.1-transduced 
Jurkat cell lines and assessed for the presence of conjugated ubiquitin using K63-
linkage-specific antibodies.  As shown in Figure 3.1A, the >90% knockdown of 
TRAF6 protein in Jurkat T cells via expression of hairpin shT6 clearly did not affect 
the amount of K63-linked ubiquitination of Bcl10 induced by PMA/ionomycin 
treatment, as compared to that observed in control cells expressing the control 
hairpin shNT.  However, the approximately 50% knockdown of TRAF2 protein in 
Jurkat T cells via expression of hairpin shT2 showed significant reduction of the 
amount of Ubn(K63)-Bcl10, similar to the reduction level shown in the control 
MALT1-knockdown cells (Figure 3.1B).  These data strongly suggest that TRAF2, but 
not TRAF6, plays a critical role upstream of the conjugation of K63-linked ubiquitin 
chain on Bcl10, although both ubiquitin E3 ligases are required for IKK activation. 
In order to test whether TAK1 kinase function is also required for Ubn(K63)-
Bcl10, similar immunoprecipitation assay was performed with Jurkat T cells that 
were pretreated with 2 μM of (5Z)-7-oxozeaenol, a TAK1-specific inhibitor, for 30 
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min prior to PMA/ionomycin stimulation.  As shown in Figure 3.1C, inhibiting TAK1 
kinase activity significantly reduced the induction level of Ubn(K63)-Bcl10 by 
PMA/ionomycin treatment, as compared to the level of ubiquitination shown in the 
DMSO vehicle control.  This result suggests that the kinase function of TAK1 also 
plays a role upstream of Bcl10 ubiquitination, although further analysis with specific 
silencing of TAK1 protein expression is necessary to confirm this conclusion. 
For several of the most active CARD11 variants that were identified and 
characterized previously, we also tested the dependence of their signaling activity 
on TRAF2.  We compared the activities of the G123D, F97Y, C49Y, V119E, G126D, 
and Y98F mutants in Jurkat T cell lines as described above that stably expressed a 
control short hairpin RNA (KD-NT) or one that targeted TRAF2 (KD-TRAF2).  As 
shown in Figure 3.1D, knockdown of TRAF2 protein level reduced the apparent 
activity of all of the mutants tested, as assessed in the Igκ2-IFN-LUC reporter assay.  
This result is consistent with our previous findings that these hyperactive CARD11 
mutants dysregulate IKK activation via spontaneously accumulation of K63-linked 
ubiquitination of Bcl10, whose induction relies on normal TRAF2 expression. 
 
Identification of a novel super-hyperactive CARD11 mutant C49Y+L251P 
 In order to generate a novel hyperactive mutant whose signaling to NF-κB is 
even more potent than ΔID for further mechanistic studies of oncogenic CARD11 
mutations, we combined the most active mutations (C49Y, F97Y and G123D) from 
both the CARD and the LATCH domain that were identified and characterized in our 
previous study.  These double mutants (C49Y+F97Y, C49Y+G123D, F97Y+G123D) 
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were tested along with the control double mutant F115L+I118V using the Igκ2-IFN-
LUC reporter assay in a transient transfection in wild-type Jurkat T cells.  As shown 
in Figure 3.2A, these double mutants were slightly more active than F115L+I118V, 
with activities ranging from 95.7 to 142.0 fold (WT control = 1.5 fold).  Next, we 
generated and tested two triple mutants (C49Y+F97Y+G123D and 
C49Y+F115L+I118V), however, the activities of these two triple mutants did not 
differ significantly from the four double mutants tested, indicating that these 
mutations from both the CARD and the LATCH domains dysregulate CARD11 with 
overlapping molecular mechanisms. 
 The OCI-Ly3 cell line, which is representative of the ABC-subtype of DLBCL, 
harbors the L251P (also known as L244P due to a different numbering scheme) 
oncogenic variant of CARD11 and relies on the dysregulated L251P signaling to NF-
κB for survival and proliferation in culture (28).  However, the detailed molecular 
mechanism of the L251P Coiled-coil domain mutant remains poorly understood.  
We therefore hypothesized that a more potent CARD11 mutant could be generated 
by combining the unknown signaling mechanisms of L251P with those of the CARD 
or the LATCH domain mutants.  In order to test this hypothesis, we combined L251P 
with C49Y, an oncogenic CARD11 mutation in the CARD domain that was previously 
reported to exist in human DLBCL patient (45).  As shown in Figure 3.2A, indeed the 
double mutant C49Y+L251P emerged as an extremely potent NF-κB activator with 
its activity reaching up to an unforeseen 1890.5 fold (WT control = 1.2 fold), an 
order of magnitude higher than the average fold change of C49Y (121.1 fold) and 
L251P (221.9 fold).  Further addition of other CARD or LATCH domain mutations to 
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the super-hyperactive mutant C49Y+L251P clearly did not further enhance its 
signaling capacity, again indicating the use of overlapping molecular mechanisms 
among these mutations. 
 The hyperactivity of the ΔID variant has been shown to depend strictly on the 
presence of all the C-terminal domains of CARD11 (L3, SH3, L4 and GUK) except for 
the PDZ domain (13).  In order to examine whether the novel super-hyperactive 
mutant C49Y+L251P is also subjected to similar restrictions, we constructed several 
C49Y+L251P variants in which the PDZ, L3, SH3, L4 or GUK domain was deleted 
respectively, and assessed their activities in a transient transfection assay using the 
Igκ2-IFN-LUC reporter in wild-type Jurkat T cells.  As expected, deleting the PDZ 
domain did not significantly alter the activity of C49Y+L251P, however, deleting the 
L4 domain also did not significantly alter the activity of C49Y+L251P (Figure 3.2B).  
Although deleting the L3, SH3 or GUK domain did reduce the activity of C49Y+L251P 
by approximately 60 to 80%, in every case the original activity is almost completely 
restored by higher expression level.  On the contrary, higher expression level clearly 
did not restore any activity of the ΔID domain deletion variants except for the 
ΔIDΔPDZ variant (Figure 3.2B).  Collectively, these data suggest that the novel 
super-hyperactive CARD11 variant C49Y+L251P probably employs other different 
signaling mechanisms that are not utilized by ΔID.  Therefore, it is likely that novel 






Super-hyperactive mutant C49Y+L251P selectively confers the ability to 
associate with Bcl10 and MALT1 
 We next determined whether the novel super-hyperactive mutant conferred 
to CARD11 an enhanced ability to interact with the signaling cofactors that have 
been previously shown to associate with CARD11 in a signal-dependent and ID-
regulated manner (13).  We coexpressed the C49Y+F97Y+G123D+L251P variant 
with FLAG-tagged Bcl10, MALT1, TRAF6, TAK1, IKKγ, or Capase-8 C360S in 
HEK293T cells and assessed the degree to which this mutant coimmunoprecipitated 
with each FLAG-tagged cofactor, using the CARD11 ΔID as positive controls.  As 
shown in Figure 3.3A, this super-hyperactive mutant selectively enhanced the 
recruitment of Bcl10 and MALT1, but not the other ID-regulated signaling cofactors 
TRAF6, TAK1, IKKγ and Caspase-8.  We then coexpressed the C49Y+L251P variant 
with FLAG-tagged Bcl10, MALT1, TRAF2 or GAKIN, in the presence or absence of 
untagged Bcl10, in HEK293T cells and performed similar coimmunoprecipitation 
assay as described above.  As shown in Figure 3.3B, the super-hyperactive mutant 
C49Y+L251P also selectively enhanced the recruitment of Bcl10 and MALT1, but not 
TRAF2 and GAKIN.  Since the levels of Bcl10 and MALT1 recruitment were not 
significantly different between the ΔID and the C49Y+L251P variants, these data 
strongly suggest that other unexamined or unknown signaling cofactors of CARD11 
whose recruitments depend on the presence of certain ID domain residues could be 




Identification of putative CARD11 signaling cofactors through protein complex 
purification of the C49Y+L251P super mutant 
 In order to identify unknown signaling components of the CBM complex, we 
attempted to purify protein cofactors that associate with the C49Y+L251P super-
hyperactive mutant from HEK293T cells.  To maximize protein complex recovery 
from cell lysates, we created CARD11 variants with C-terminal Biotag, a specific 
biotin acceptor peptide that has been described previously (62).  Using the calcium 
phosphate transfection method, we then coexpressed either wild-type CARD11 or 
the C49Y+L251P super mutant with the biotin ligase BirA (62) in HEK293T cells.  
Biotinylated CARD11 complexes were pulled-down efficiently, as indicated by more 
than 95% of CARD11 protein depletion after 2 h of incubation with the Neutravidin 
beads, which is difficult to achieve by other epitope tags after prolonged incubation.  
To further purify the associated proteins, we fractionated them by three differential 
elutions performed as described in Experimental Procedures and in Figure 3.4.  For 
small-scale purification, silver staining was used to analyze each elution fraction on 
SDS-PAGE gel as shown in Figure 3.4A.  We readily observed several extra protein 
bands that get recruited to the C49Y+L251P variant at higher levels, as compared to 
the wild-type CARD11 and the negative controls.  Using the same approach, we 
scaled-up the purification by 10 fold and stained the SDS-PAGE gel with colloidal 
blue (Figure 3.4B).  Protein bands of interest were identified by mass spectrometry 
and the results were analyzed and summarized as shown in Figure 3.4B. 
Among these identified proteins, the Casein kinase CK1α emerged as the 
most significant protein cofactor whose recruitment to the C49Y+L251P variant is at 
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a much higher level as compared to that observed in the wild-type CARD11 control.  
These data also suggest that CK1α binds so tightly to the C49Y+L251P variant that 
the interaction can only be disrupted by denaturating elution condition.  Consistent 
with this finding, CK1α has been shown to play a critical role in lymphoma cell 
survival as shRNA-mediated knockdown of CK1α in several ABC-DLBCL cell lines 
including OCI-Ly3 (which harbors the L251P variant) was toxic to these lymphoma 
cells (50).  CK1α has also been shown to rely on both the Coiled-coil and the ID 
domains of CARD11 for its association (50), suggesting that the ΔID variant is 
missing certain CK1α binding sites in the ID domain, which could potentially explain 
why the ΔID variant is much less active than the C49Y+L251P super mutant. 
In addition to CK1α, we have also identified other known cofactors of 
CARD11 including Bcl10, MALT1 and IKKγ (Figure 3.4B), although the abundance of 
these proteins was much lower than that of CK1α, indicating a low steady-state level 
of the CBM complex using our purification method in HEK293T cells.  From almost 
all elution fractions in protein bands between 25 to 35 kDa, we also identified an 
ubiquitin E3 ligase STUB1, which has been shown to be required for TCR-induced 
NF-κB activation and IL-2 production (59).  Interestingly, CARD11 has been shown 
to be a substrate of STUB1 for K27-linked ubiquitination, although the significance 
of such modification on CARD11 is not clear.  Collectively, the presence of these 
known signaling cofactors of CARD11 in our purification and mass spectrometry 
identification strengthened our confidence about the validity of the other putative 
protein cofactors that were also isolated and identified in this screen. 
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Among all the putative protein cofactors identified, the ubiquitin-specific-
processing protease USP7 was the most promising candidate.  As shown in Figure 
3.4B, the protein band that contained a relatively abundant amount of USP7 was 
clearly absent from the wild-type CARD11 control lane, indicating the dysregulated 
recruitment of USP7 to the C49Y+L251P variant.  Another promising candidate that 
emerged from this study was the phosphoserine-binding signaling adapter 14-3-3 ε 
(YWHAE), which was coincidently isolated from another protein-protein interaction 
screen in which the truncated L251P CARD11 variant was used as bait protein.  As 
shown in Figure 3.4B, the protein bands that contained 14-3-3 ε were clearly much 
more intense than those corresponding bands in the wild-type CARD11 control lane, 
indicating dysregulated recruitment of 14-3-3 ε to the C49Y+L251P variant.  We also 
identified previously uncharacterized ubiquitin E3 ligases in this study, including 
UBE3C, UBE3D and RNF114.  Among these E3 ligases, our mass spectrometry data 
suggest that UBE3C is probably the most significant candidate, as supported by the 
presence of an abundant amount of representative peptides in the indicated gel 
band shown in Figure 3.4B. 
 
Discussion 
Although it is clear that oncogenic CARD11 mutations can elicit intracellular 
accumulation of the K63-linked ubiquitination of Bcl10, the specific E3 ligase that 
catalyzes this process remains unidentified.  Our data suggest that TRAF2 and TAK1 
are required cofactors for the induction of Ubn(K63)-Bcl10 upon antigen receptor 
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signaling.  Similar to TRAF6, TRAF2 has been shown previously (30) to associate 
with the C-terminal domain of MALT1 (residues 334-824), however, our data clearly 
showed that TRAF6 could be dispensable for the induction of Ubn(K63)-Bcl10 upon 
PMA/ionomycin stimulation.  Furthermore, a role for TRAF2 in Ubn(K63)-Bcl10 is 
supported by the finding that TRAF2 is associated with Bcl10 and a MALT1 fusion 
protein found in MALT lymphoma (64, 65).  Our finding is supported by another 
previous study that identified mutations in both TRAF2 and TAK1 as the culprits of 
NF-κB dysregulation in human diffuse large B-cell lymphoma (45).  It will be 
interesting and informative to examine whether these TRAF2 and TAK1 oncogenic 
mutations could also function to spontaneously induce the accumulation of 
Ubn(K63)-Bcl10.  Our data do not exclude the possibility that TRAF2 and TAK1 are 
required for the activation of another unidentified ubiquitin E3 ligase that directly 
catalyzes the conjugation of K63-linked ubiquitin chain on Bcl10 during normal 
antigen receptor signaling. 
Our study identified an extremely potent double mutant of CARD11 that 
synergizes the signaling potentials of both the C49Y (CARD) and the L251P (Coiled-
coil) oncogenic variants.  According to protein expression data obtained in transient 
transfection in HEK293T cells, the protein expression level (per ng of transfected 
plasmid) of this super mutant is actually lower than that of wild-type CARD11 or the 
C49Y variant.  Therefore, it is unlikely that the hyperactivity of this super mutant 
emerged as a result of protein overexpression in Jurkat T cells.  Interestingly, adding 
the LATCH domain mutations to the C49Y+L251P variant did not further enhance its 
signaling capacity, indicating that the LATCH domain function has already been 
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dysregulated by the presence of both C49Y and L251P mutations.  It is currently 
unclear whether a complete deletion of the LATCH domain will have an impact on 
the hyperactive signaling of the C49Y+L251P variant.  We were surprised to find 
that deleting any one of the C-terminal domains of CARD11 (L3, SH3, L4 and GUK) in 
the context of the C49Y+L251P super mutant failed to completely abolish its 
hyperactivity.  However, it is still unclear whether all of these C-terminal domains 
are dispensable for the hyperactive signaling of this super mutant. 
The quadruple mutant C49Y+F97Y+G123D+L251P, which is approximately 
10 fold more active than ΔID for NF-κB signaling, clearly did not enhance the 
recruitment of TRAF6, TAK1, IKKγ or Caspase-8 to CARD11, as compared to the ΔID 
variant.  The discrepancy between signaling activity and cofactor binding suggests 
that the ID domain probably harbors critical activation and cofactor association 
domains that are both deleted in the ΔID variant.  It would be interesting to perform 
similar cofactor binding studies with a ΔID variant in which the C49Y and L251P 
mutations are incorporated, and test whether this ID-deleted super mutant could 
maintain its signaling capacity to NF-κB even in the absence of the ID domain. 
A major finding of our protein complex purification using the biotinylated 
C49Y+L251P variant was the identification of CK1α as a dysregulation target of 
oncogenic CARD11 mutations.  It remains to be seen whether this enhanced binding 
of CK1α is dysregulated specifically by the L251P Coiled-coil mutation and not by 
the C49Y CARD mutation.  It is also unclear whether CK1α is required for the 
induction of K63-linked ubiquitination of Bcl10 upon antigen receptor or oncogenic 
CARD11 signaling.  Furthermore, the detailed molecular mechanism of how CK1α 
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regulates the function of the CBM complex during normal antigen receptor signaling 
remains poorly understood.  In Jurkat T cells stably expressing the C49Y+L251P 
variant, we also observed enhanced CK1α recruitment to mutant CARD11, as 
compared to the wild-type CARD11 control (data not shown).  Interestingly, our 
recent data have confirmed that the enhanced CK1α recruitment to the C49Y+L251P 
variant occurred even in Bcl10 knocked-out Jurkat T cells, suggesting that CK1α is 
capable of interacting with CARD11 in a different CARD11 complex upstream of or 
independent of the formation of the CBM complex.  Our mass spectrometry data also 
suggest a potential dysregulation of CKIIα recruitment to CARD11 by the 
C49Y+L251P variant.  Although CKIIα has not been linked to CARD11 during normal 
antigen receptor signaling, recently the Casein kinase-2 interacting protein-1 (CKIP-
1), which was originally identified as an interacting protein of CKIIα, has been 
shown to interact with CARD11 and negatively regulate T cell activation (66).  It 
remains to be seen whether CKIIα is an essential regulator of CARD11 during 
antigen receptor signaling. 
Although we have identified a list of putative protein binding partners using 
CARD11 as the major bait, it is important to point out that some of these identified 
protein cofactors may not be directly interacting with CARD11.  Instead, their 
association with CARD11 could be mediated through the dysregulated binding of 
other protein cofactors such as CK1α, Bcl10, MALT1 and IKKγ.  A secondary screen 
using some recently emerging genetic tools such as CRISPR and TALEN to knock out 
the expression of these candidates in Jurkat T cells would be necessary to confirm 




Figure 3.1:  An E3 ubiquitin ligase TRAF2 and TAK1 kinase are required for 
PMA/ionomycin-induced K63-linked ubiquitination of Bcl10. 
(A) Knockdown of TRAF6 in Jurkat T cells via expression of hairpin shT6 did not 
affect the induction of Ubn(K63)-Bcl10 by PMA/ionomycin treatment, as compared 
to that observed in control cells expressing the control hairpin shNT.  Cells were 
treated with or without 50 ng/ml PMA and 1 μM ionomycin for 20 minutes before 
lysis and assayed for Ubn(K63)-Bcl10 levels as described in Experimental 
Procedures. 
(B) Knockdown of TRAF2 or MALT1 via expression of hairpin shT2 or shM1 
respectively reduced induction of Ubn(K63)-Bcl10 by PMA/ionomycin treatment.  
Cells were treated as described in (A). 
(C) Inhibition of TAK1 kinase activity reduced induction of Ubn(K63)-Bcl10 by 
PMA/ionomycin treatment.  Jurkat T cells were pretreated with either DMSO vehicle 
(-) or 2 μM (5Z)-7-oxozeaenol (5Z-7-o) (+) for 30 min prior to PMA/ionomycin 
treatment and lysis as described in (A). 
(D) Hyperactive CARD11 variants require TRAF2 for NF-κB activation.  Jurkat T cells 
stably expressing hairpin that targets TRAF2 (KD-TRAF2) or a control hairpin (KD-
NT), were transfected with 200 ng of CSK-LacZ and 1,500 ng of Igκ2-IFN-LUC in the 
presence of the indicated amounts of expression vectors for the indicated CARD11 








Figure 3.2:  Oncogenic CARD11 mutations C49Y (CARD) and L251P (Coiled-coil) 
synergize their respective signaling capacity to generate a super-hyperactive 
mutant that no longer requires PDZ, L3, SH3, L4 or GUK for signaling to NF-κB. 
(A and B) Jurkat T cells were transfected with 200 ng of CSK-LacZ and 1,500 ng of 
Igκ2-IFN-LUC in the presence of the indicated amounts of expression vectors for the 
























Figure 3.3:  Super-hyperactive mutant C49Y+L251P enhances the ability of 
CARD11 to associate with Bcl10 and MALT1, but not other signaling cofactors. 
(A) HEK293T cells were transfected with 30 to 55 ng of expression vectors for the 
indicated myc-CARD11 variants and either 25 to 30 ng of FLAG-Bcl10, 250 to 300 ng 
of FLAG-MALT1, 50 to 60 ng of FLAG-TRAF6, 50 to 60 ng of FLAG-TAK1, 250 to 300 
ng of FLAG-IKKγ, or 250 to 300 ng of FLAG-Caspase-8-C360S, as indicated.  Anti-
FLAG immunoprecipitations were performed as described in Experimental 
Procedures and analyzed by western blot with the indicated primary antibodies. 
(B) HEK293T cells were transfected with 40 to 60 ng of expression vectors for the 
indicated myc-CARD11 variants and either 25 to 30 ng of FLAG-Bcl10, 250 to 300 ng 
of FLAG-MALT1, 250 to 300 ng of FLAG-TRAF2, 300 to 400 ng of untagged Bcl10 
along with 500 to 600 ng of FLAG-MALT1 or FLAG-TRAF2, or 250 to 300 ng of 
FLAG-GAKIN, as indicated.  Anti-FLAG immunoprecipitations were performed as 
described in Experimental Procedures and analyzed by western blot with the 





















Figure 3.4:  Several putative CARD11 signaling cofactors were identified 
through protein complex purification of the super-hyperactive CARD11 
mutant C49Y+L251P. 
HEK293T cells were transfected with 5 to 12 μg per 15-cm plate of expression 
vectors for the indicated myc-CARD11-Biotag variants and 1.2 μg per 15-cm plate of 
FLAG-BirA biotin ligase.  Biotin pulldowns were performed as described in 
Experimental Procedures.  NaCl and SDS elutions were collected sequentially as 
indicated, resolved by 10% SDS-PAGE, and detected by (A) silver stain or (B) 
colloidal blue stain.  Gel slices containing protein bands of interest were identified 












































Hyperactive CARD11 Mutations in the CARD and LATCH Domains 
 CARD11-mediated antigen receptor signaling to NF-κB is a critical pathway 
for normal lymphocyte activation and proliferation.  As the activation level of NF-κB 
needs to be exquisitely tuned by the immune system in order to prevent chaotic 
malfunction in either direction, an intricate network of both positive and negative 
regulation has evolved to protect the host from diseases.  During normal signaling, 
CARD11 is regulated by its conformational transition between a closed, inactive 
state and an open, active scaffold.  This transition of CARD11 is dysregulated by 
lymphoma-associated CARD11 mutations that induce spontaneous signaling.  Since 
almost all of the identified mutations were located within the Coiled-coil domain, we 
conducted a high-throughput quantitative signaling screen and identified new 
CARD11 hyperactive variants in both the CARD and LATCH domains.  Mechanistic 
characterization suggest that these gain-of-function mutations disrupt the 
autoinhibitory ID domain binding, promote Bcl10 association and K63-linked 
polyubiquitination, NF-κB activation, and human lymphoma cell survival. 
The main conclusion that emerges from our data is that the intramolecular 
regulation of CARD11 that allows for its signal-dependent activation by antigen 
receptor signaling also results in a vulnerability to mutation that can be exploited by 
lymphomas to bypass normal controls and induce NF-κB and its pro-proliferative 
and anti-apoptotic target genes.  Our data clearly suggest that hyperactive CARD11 
mutations can also emerge in domains outside of the Coiled-coil domain by 
disrupting the CARD-Coiled-coil-ID autoinhibitory binding.  Based on our current 
working model of the CARD11 scaffold transition, we should be able to identify 
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hyperactive mutations within the ID domain by the same token.  However, we have 
not yet been able to identify any missense mutation in the ID domain by the random 
mutagenesis approach, and lymphoma-associated oncogenic ID mutation has never 
been identified there either.  The absence of hyperactive ID domain mutations 
conflicts with our current model of CARD11 scaffold transition and suggests that a 
major revision of this simple model is necessary. 
Unexpectedly, our screening also identified a surprisingly high density of 
mutations in the LATCH domain, a short nineteen-residue region between the CARD 
and Coiled-coil that plays a significant role in autoinhibition by the ID.  It is currently 
unclear how the LATCH domain participates in the CARD-Coiled-coil-ID 
intramolecular interaction and autoinhibitory function.  Interestingly, the S116 and 
T117 residues within the LATCH domain have been shown to serve as substrates for 
phosphorylation by CaMKII (55) and PKCβ (25) respectively. 
  Our data emphasize the importance of K63-linked polyubiquitinated Bcl10 
as a signaling intermediate whose accumulation is dysregulated by hyperactive 
CARD11 mutants and correlates with the enhanced recruitment of unconjugated 
Bcl10 to hyperactive CARD11 mutants.  During normal antigen receptor signaling, 
K63-linked polyubiquitinated Bcl10 is induced only transiently (22), and is rapidly 
removed by negative feedback mechanisms that serve to terminate signaling (41–
43).  It is clear that in order to fully understand how both normal and dysregulated 
CARD11 signaling occurs, further studies are necessary to identify the E3 ligase that 
ubiquitinates Bcl10 through K63-linkages, explain how the association with CARD11 
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promotes this modification, and elucidate how exactly Ubn(K63)-Bcl10 activates IKK 
kinase activity. 
 Although none of the hyperactive CARD or LATCH domain mutations showed 
enhanced recruitment of MALT1, TRAF6, and TAK1 cofactors to CARD11, the six 
most hyperactive variants tested did require MALT1, TRAF6, and TAK1 for signaling 
to NF-κB.  These cofactors have been shown by other groups to be required for IKK 
kinase induction downstream of antigen receptor engagement.  MALT1 is required 
for K63-linked ubiquitination of Bcl10 (22), and has also been implicated in K63-
linked ubiquitination of IKKγ (44). TRAF6 also contributes to IKKγ K63-linked 
ubiquitination (30), but does not appear to be required for the induction of K63-
linked ubiquitination of Bcl10.  TAK1 has been shown to mediate IKK kinase subunit 
phosphorylation during signaling (40).  An alternative dysregulation mechanism of 
hyperactive CARD11 variants can be achieved through reduced association with 
inhibitory cofactors such as GAKIN (29).  Preliminary data suggest that several 
hyperactive CARD11 variants tested did indeed reduce their association with GAKIN, 
as compared to the wild-type CARD11 control in a coimmunoprecipitation assay in 
HEK293T cells.  This observation is consistent with our previous finding that GAKIN 
can compete with Bcl10 for binding sites in both the CARD and Coiled-coil domains 
upon PMA/ionomycin stimulation. 
 Most of the hyperactive variants that we tested had enough enhanced activity 
to promote the proliferation and survival of the ABC DLBCL-derived OCI-Ly3 line in 
culture, indicating their oncogenic potential in human lymphoma cells.  In fact, while 
our work was in progress, several studies reported the presence of CARD11 
94 
 
mutations in the CARD and LATCH domains in human biopsies of DLBCL, which 
provide further validation of our screening approach.  Interestingly, six of these are 
identical to mutations that we isolated in our screen, and four other reported 
mutations occur at the same position as those we found in our screen, but mutated 
to different residues.  Although these studies did not demonstrate a functional effect 
of the mutations in the context of the cancers in which they were sequenced, our 
data provide a mechanistic characterization that can explain how the substitutions 
could lead to dysregulated NF-κB activity and promote proliferation and survival. 
 We can easily expand our quantitative high-throughput screen to detect 
other hyperactive variants in other domains of CARD11 such as the Coiled-coil 
domain.  Our modular screening approach makes it straightforward to substitute 
the target protein that undergoes mutation and screening, which allows for the 
efficient discovery of hyperactive variants that emerge in the other proteins (such as 
MyD88, CD79A or CD79B) and contribute to the oncogenesis of NF-κB-dependent 
cancers.  By replacing the NF-κB reporter with that of another transcription factor, 
the screen could readily be adopted to identify variants of other gene regulators that 
promote tumorigenesis in other cell types. 
In summary, our results identify hyperactive CARD11 mutations with 
oncogenic potential, provide a mechanistic explanation for their signaling potency, 
and offer a straightforward method for the discovery of variants that promote the 





Super-hyperactive Mutant and Putative Regulators of the CBM Complex 
In order to fully understand how both normal and dysregulated CARD11 
signaling occurs, we conducted further studies to identify the specific E3 ligase that 
ubiquitinates Bcl10 through K63-linkages.  Several E3 ubiquitin ligases including 
TRAF6, TRAF2, MIB2, and STUB1 have previously been shown to associate with 
CARD11 or Bcl10 upon antigen receptor signaling.  Our data suggest that TRAF2 and 
TAK1, but not TRAF6, are required for the induction of K63-linked ubiquitination of 
Bcl10.  However, we have not yet examined the requirement of MIB2 and STUB1 for 
the induction of Ubn(K63)-Bcl10.  According to previous reports, TRAF2 could 
associate with the CARD domain of Bcl10 and the C-terminal domain of MALT1, 
although it is unclear whether these interactions were direct or mediated by other 
endogenous bridging factors.  As MALT1 is required for the induction of Ubn(K63)-
Bcl10 and constitutively associated with Bcl10, it is possible that MALT1 could serve 
as a bridging cofactor that helps recruit TRAF2 to Bcl10.  Nevertheless, it remains 
possible that TRAF2 and TAK1 function to activate another unidentified ubiquitin 
E3 ligase that functions directly to catalyze the conjugation of K63-linked ubiquitin 
chain on Bcl10 during normal antigen receptor signaling. 
The identification of an extremely potent double oncogenic CARD11 mutant 
C49Y+L251P suggests that the hyperactivity of ΔID is far below the maximum 
potential of CARD11.  However, we are aware that the hyperactivity of this super 
mutant is transient and subjected to strong negative feedback mechanisms in Jurkat 
T cells, as indicated by much less NF-κB activation in cells stably expressing the 
C49Y+L251P variant.  Imaging data show that the localization of this super mutant 
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tends to adopt a punctate pattern with lower protein expression, as compared to the 
wild-type, C49Y, and L251P controls.  Interestingly, cytosolic CK1α has been shown 
to reorganized into punctate structures that colocalized with CD3 clusters upon TCR 
activation (50).  Our cofactor purification data also identified CK1α as the major 
dysregulation target of the C49Y+L251P super mutant.  As CK1α has been shown to 
confer a dual ‘gating’ function which first promotes and then terminates receptor-
induced NF-κB activation, this kinase could serve as a negative feedback mechanism 
to downmodulate the super-hyperactive signaling of the C49Y+L251P variant in the 
long run, presumably to protect lymphocytes from the toxic side effects of over-
activation.  Further studies are necessary to clarify the molecular details of CK1α 
action on CARD11 during normal antigen receptor and dysregulated lymphoma 
signaling to NF-κB. 
Although deleting any one of the C-terminal domains of CARD11 (L3, SH3, L4 
and GUK) in the context of the C49Y+L251P super mutant failed to completely 
abolish its hyperactivity, it is unclear whether all of these C-terminal domains are 
simply dispensable for the hyperactive signaling of this super mutant.  If that turns 
out to be true, it would suggest that a C-terminal truncated mini-CARD11 could still 
assemble into an active scaffold for signal relay.  Further study is also needed to 
determine whether the LATCH domain, the CARD-Coiled-coil linker, is absolutely 
required for the hyperactive signaling of the C49Y+L251P variant. 
Even with much weaker activity as compared to the C49Y+L251P super 
mutant, the ΔID variant remains to be better at recruiting signaling cofactors.  The 
discrepancy between signaling activity and cofactor binding suggests that the ID 
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domain probably harbors critical activation and cofactor association domains that 
are both deleted in the ΔID variant.  It would be interesting to perform similar 
cofactor binding studies with a ΔID variant in which the C49Y and L251P mutations 
are incorporated, and test whether this ID-deleted super mutant could maintain its 
signaling capacity to activate NF-κB even in the absence of the ID domain. 
It remains to be seen whether the enhanced binding of CK1α is dysregulated 
specifically by the L251P Coiled-coil mutation and not by the C49Y CARD mutation.  
As CK1α depends on the Coiled-coil and ID domain for association with CARD11, it 
would be more consistent that the L251P but not the C49Y mutation could function 
to expose CK1α binding sites within the Coiled-coil domain for association, possibly 
through disruption of the Coiled-coil-ID autoinhibitory binding.  This would be in 
parallel with the C49Y mutation which is known to enhance Bcl10 association 
through disrupting the CARD-ID autoinhibitory binding.  This would also help 
explain the synergy between the C49Y and the L251P mutations, since they may 
combine at least two positive non-overlapping mechanisms to maximize the 
signaling capacity of CARD11.  Interestingly, our recent data have confirmed that the 
enhanced CK1α recruitment to the C49Y+L251P variant occurred even in Bcl10 
knocked-out Jurkat T cells, suggesting that CK1α is capable of interacting with 
CARD11 in a different CARD11 complex upstream of the formation of the CBM 
complex.  It would be informative to examine whether CK1α recruitment to CARD11 
during normal antigen receptor signaling requires the activity of PKCθ or PKCβ. 
Our protein complex purification method from mammalian cell lysates is 
highly efficient as the Biotag peptide allows for almost complete recovery of the bait 
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protein during a short incubation time with the Neutravidin resin.  The method also 
does not require the addition of excessive amount of antibodies and therefore helps 
eliminate some interfering protein bands in the background and results in more 
sensitive detection of differential protein bands.  The strong interaction between 
biotin and Neutravidin (Kd = 10-15 M) makes the biotinylated bait protein resistant to 
harsh elution conditions and thereby enables the separation of prey proteins from 
the abundant biotinylated bait proteins on the resin. 
 In summary, our results identify critical components during the assembly of 
K63-linked polyubiquitination of Bcl10, a novel super-hyperactive CARD11 mutant 
that synergizes dysregulation mechanisms from both the CARD and the Coiled-coil 
domains, and several putative protein regulators of the CARD11 scaffold complex 
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